


Discover The Elegance Of A Hybrid



At first glance, it's the beauty of the hybrid Lily that catches the eye. The vibrant color. The delicately shaped petals. But study it more closely, and its *elegance* becomes apparent—a gentle blend of softness and strength.

At first glance, it's the enhanced performance of Vaseretic[®] that catches the eye. But study Vaseretic[®] more closely, and its *elegance* becomes apparent. The way its one-tablet, once-a-day

dosage minimizes multiple medications. Minimizes the number of insurance copayments. And minimizes potassium supplementation.

A hybrid blending of tolerability and power that's available for the right patient. Vaseretic[®] is indicated for the treatment of hypertension in patients for whom combination therapy is appropriate.

And an elegant discovery for your practice.

VASERETIC[®] 10-25 *Next*
Enalapril Maleate-Hydrochlorothiazide

Vaseretic[®] is contraindicated in patients who are hypersensitive to any component of this product or to other sulfonamide-derived drugs and in patients with a history of angioedema related to previous treatment with an ACE inhibitor.

Dosage must be individualized; the fixed combination is not for initial therapy.

Evaluation of the hypertensive patient should always include assessment of renal function.

For a Brief Summary of Prescribing Information, see adjacent pages.

USE IN PREGNANCY: When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, Vaseretic[®] (Enalapril Maleate-Hydrochlorothiazide) should be discontinued as soon as possible. See WARNINGS, Fetal/Neonatal Morbidity and Mortality.

TABLETS **VASERETIC®** (ENALAPRIL MALEATE-HYDROCHLOROTHIAZIDE)

USE IN PREGNANCY: When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, VASERETIC® (Enalapril Maleate-Hydrochlorothiazide) should be discontinued as soon as possible. See WARNINGS, Fetal/Neonatal Morbidity and Mortality.

CONTRAINDICATIONS: VASERETIC is contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angioedema related to previous treatment with an angiotensin converting enzyme inhibitor. Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs.

WARNINGS: General; Enalapril Maleate; Hypotension: Excessive hypotension was rarely seen in uncomplicated hypertensive patients but is a possible consequence of enalapril use in severely salt/volume depleted persons such as those treated vigorously with diuretics or patients on dialysis.

Syncope has been reported in 1.3 percent of patients receiving VASERETIC. In patients receiving enalapril alone, the incidence of syncope is 0.5 percent. The overall incidence of syncope may be reduced by proper titration of the individual components. (See PRECAUTIONS, Drug Interactions, and ADVERSE REACTIONS.)

In patients with severe congestive heart failure, with or without associated renal insufficiency, excessive hypotension has been observed and may be associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death. Because of the potential fall in blood pressure in these patients, therapy should be started under very close medical supervision and whenever the dose of enalapril and/or diuretic is increased. Similar considerations may apply to patients with ischemic heart or cerebrovascular disease, in whom an excessive fall in blood pressure could result in a myocardial infarction or cerebrovascular accident.

If hypotension occurs, the patient should be placed in the supine position and, if necessary, receive an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further doses, which usually can be given without difficulty once the blood pressure has increased after volume expansion.

Angioedema: Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported in patients treated with angiotensin converting enzyme inhibitors, including enalapril. This may occur at any time during treatment. In such cases VASERETIC should be promptly discontinued and appropriate therapy and monitoring should be provided until complete and sustained resolution of signs and symptoms has occurred. In instances where swelling has been confined to the face and lips the condition has generally resolved without treatment, although antihistamines have been useful in relieving symptoms. Angioedema associated with laryngeal edema may be fatal. Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, appropriate therapy, e.g., subcutaneous epinephrine solution 1:1000 (0.3 mL to 0.5 mL) and/or measures necessary to ensure a patent airway, should be promptly provided. (See ADVERSE REACTIONS.)

Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor (see also CONTRAINDICATIONS).

Neutropenia/Agranulocytosis: Another angiotensin converting enzyme inhibitor, captopril, has been shown to cause agranulocytosis and bone marrow depression, rarely in uncomplicated patients but more frequently in patients with renal impairment especially if they also have a collagen vascular disease. Available data from clinical trials of enalapril are insufficient to show that enalapril does not cause agranulocytosis at similar rates. Marketing experience has revealed several cases of neutropenia or agranulocytosis in which a causal relationship to enalapril cannot be excluded. Periodic monitoring of white blood cell counts in patients with collagen vascular disease and renal disease should be considered.

Hydrochlorothiazide: Thiazides should be used with caution in severe renal disease. In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects of the drug may develop in patients with impaired renal function.

Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.

Sensitivity reactions may occur in patients with or without a history of allergy or bronchial asthma.

The possibility of exacerbation or activation of systemic lupus erythematosus has been reported.

Lithium generally should not be given with thiazides (see PRECAUTIONS, Drug Interactions, Enalapril Maleate and Hydrochlorothiazide).

Pregnancy, Enalapril-Hydrochlorothiazide: There was no teratogenicity in rats given up to 90 mg/kg/day of enalapril (150 times the maximum human dose) in combination with 10 mg/kg/day of hydrochlorothiazide (2 1/2 times the maximum human dose) or in mice given up to 30 mg/kg/day of enalapril (50 times the maximum human dose) in combination with 10 mg/kg/day of hydrochlorothiazide (2 1/2 times the maximum human dose). At these doses, fetotoxicity expressed as a decrease in average fetal weight occurred in both species. No fetotoxicity occurred at lower doses; 30/10 mg/kg/day of enalapril-hydrochlorothiazide in rats and 10/10 mg/kg/day of enalapril-hydrochlorothiazide in mice.

When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, VASERETIC should be discontinued as soon as possible. (See Enalapril Maleate, Fetal/Neonatal Morbidity and Mortality, below.)

Enalapril Maleate; Fetal/Neonatal Morbidity and Mortality: ACE inhibitors can cause fetal and neonatal morbidity and death when administered to pregnant women. Several dozen cases have been reported in the world literature. When pregnancy is detected, ACE inhibitors should be discontinued as soon as possible.

The use of ACE inhibitors during the second and third trimesters of pregnancy has been associated with fetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death. Oligohydramnios has also been reported, presumably resulting from decreased fetal renal function; oligohydramnios in this setting has been associated with fetal limb contractures, craniofacial deformation, and hypoplastic lung development. Prematurity, intrauterine growth retardation, and patent ductus arteriosus have also been reported, although it is not clear whether these occurrences were due to the ACE-inhibitor exposure.

These adverse effects do not appear to have resulted from intrauterine ACE-inhibitor exposure that has been limited to the first trimester. Mothers whose embryos and fetuses are exposed to ACE inhibitors only during the first trimester should be so informed. Nonetheless, when patients become pregnant, physicians should make every effort to discontinue the use of VASERETIC as soon as possible.

Rarely (probably less often than once in every thousand pregnancies), no

10
mg



25
mg

alternative to ACE inhibitors will be found. In these rare cases, the mothers should be apprised of the potential hazards to their fetuses, and serial ultrasound examinations should be performed to assess the intrauterine environment.

If oligohydramnios is observed, VASERETIC should be discontinued unless it is considered lifesaving for the mother. Contraction stress testing (CST), a non-stress test (NST), or biophysical profiling (BPP) may be appropriate, depending upon the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury.

Infants with histories of *in utero* exposure to ACE inhibitors should be closely observed for hypotension, oliguria, and hyperkalemia. If oliguria occurs, attention should be directed toward support of blood pressure and renal perfusion. Exchange transfusion or dialysis may be required as means of reversing hypotension and/or substituting for disordered renal function. Enalapril, which crosses the placenta, has been removed from neonatal circulation by peritoneal dialysis with some clinical benefit, and theoretically may be removed by exchange transfusion, although there is no experience with the latter procedure.

No teratogenic effects of enalapril were seen in studies of pregnant rats, and rabbits. On a mg/kg basis, the doses used were up to 333 times (in rats), and 50 times (in rabbits) the maximum recommended human dose.

Hydrochlorothiazide; Teratogenic Effects: Reproduction studies in the rabbit, the mouse and the rat at doses up to 100 mg/kg/day (50 times the human dose) showed no evidence of external abnormalities of the fetus due to hydrochlorothiazide. Hydrochlorothiazide given in a two-litter study in rats at doses of 4 - 5.6 mg/kg/day (approximately 1 - 2 times the usual daily human dose) did not impair fertility or produce birth abnormalities in the offspring. Thiazides cross the placental barrier and appear in cord blood.

Nonteratogenic Effects: These may include fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions which have occurred in the adult.

PRECAUTIONS: General; Enalapril Maleate; Impaired Renal Function: As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients with severe congestive heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with angiotensin converting enzyme inhibitors, including enalapril, may be associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death.

In clinical studies in hypertensive patients with unilateral or bilateral renal artery stenosis, increases in blood urea nitrogen and serum creatinine were observed in 20 percent of patients. These increases were almost always reversible upon discontinuation of enalapril and/or diuretic therapy. In such patients renal function should be monitored during the first few weeks of therapy.

Some patients with hypertension or heart failure with no apparent pre-existing renal vascular disease have developed increases in blood urea and serum creatinine, usually minor and transient, especially when enalapril has been given concomitantly with a diuretic. This is more likely to occur in patients with pre-existing renal impairment. Dosage reduction of enalapril and/or discontinuation of the diuretic may be required.

Evaluation of the hypertensive patient should always include assessment of renal function.

Hemodialysis Patients: Anaphylactoid reactions have been reported in patients dialyzed with high-flux membranes (e.g., AN 69®) and treated concomitantly with an ACE inhibitor. In these patients consideration should be given to using a different type of dialysis membrane or a different class of antihypertensive agent.

Hyperkalemia: Elevated serum potassium (greater than 5.7 mEq/L) was observed in approximately one percent of hypertensive patients in clinical trials treated with enalapril alone. In most cases these were isolated values which resolved despite continued therapy, although hyperkalemia was a cause of discontinuation of therapy in 0.28 percent of hypertensive patients. Hyperkalemia was less frequent (approximately 0.1 percent) in patients treated with enalapril plus hydrochlorothiazide. Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes, which should be used cautiously, if at all, with enalapril. (See Drug Interactions.)

Cough: Cough has been reported with the use of ACE inhibitors. Characteristically, the cough is nonproductive, persistent and resolves after discontinuation of therapy. ACE inhibitor-induced cough should be considered as part of the differential diagnosis of cough.

Surgery/Anesthesia: In patients undergoing major surgery or during anesthesia with agents that produce hypotension, enalapril may block angiotensin II formation secondary to compensatory renin release. If hypotension occurs and is considered to be due to this mechanism, it can be corrected by volume expansion.

Hydrochlorothiazide: Periodic determination of serum electrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals. All patients receiving thiazide therapy should be observed for clinical signs of fluid or electrolyte imbalance: hyponatremia, hypochloremic alkalosis, and hypokalemia. Serum and urine electrolyte determinations are particularly important when the patient is vomiting excessively or receiving parenteral fluids. Warning signs or symptoms of fluid and electrolyte imbalance, irrespective of cause, include dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, confusion, seizures, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea and vomiting.

Hyperkalemia may develop, especially with brisk diuresis, when severe cirrhosis is present, or after prolonged therapy. Interference with adequate oral electrolyte intake will also contribute to hyperkalemia. Hyperkalemia may cause cardiac arrhythmia and may also sensitize or exaggerate the response of the heart to the toxic effects of digitalis (e.g., increased ventricular irritability). Because enalapril reduces the production of aldosterone, concomitant therapy with enalapril attenuates the diuretic-induced potassium loss (see Drug Interactions, Agents Increasing Serum Potassium).

Although any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (as in liver disease or renal disease), chloride replacement may be required in the

treatment of metabolic alkalosis.

Dilutional hyponatremia may occur in edematous patients in hot weather; appropriate therapy is water restriction, rather than administration of salt except in rare instances when the hyponatremia is life-threatening. In actual salt depletion, appropriate replacement is the therapy of choice.

Hyperuricemia may occur or frank gout may be precipitated in certain patients receiving thiazide therapy.

In diabetic patients dosage adjustments of insulin or oral hypoglycemic agents may be required. Hyperglycemia may occur with thiazide diuretics. Thus latent diabetes mellitus may become manifest during thiazide therapy.

The antihypertensive effects of the drug may be enhanced in the postsympathectomy patient.

If progressive renal impairment becomes evident consider withholding or discontinuing diuretic therapy.

Thiazides have been shown to increase the urinary excretion of magnesium; this may result in hypomagnesemia.

Thiazides may decrease urinary calcium excretion. Thiazides may cause intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Marked hypercalcemia may be evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function.

Increases in cholesterol and triglyceride levels may be associated with thiazide diuretic therapy.

Information for Patients; Angioedema: Angioedema, including laryngeal edema, may occur at any time during treatment with angiotensin converting enzyme inhibitors, including enalapril. Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips, tongue, difficulty in swallowing or breathing) and to take no more drug until they have consulted with the prescribing physician.

Hypotension: Patients should be cautioned to report lightheadedness especially during the first few days of therapy. If actual syncope occurs, the patients should be told to discontinue the drug until they have consulted with the prescribing physician.

All patients should be cautioned that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. Other causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; patients should be advised to consult with the physician.

Hyperkalemia: Patients should be told not to use salt substitutes containing potassium without consulting their physician.

Neutropenia: Patients should be told to report promptly any indication of infection (e.g., sore throat, fever) which may be a sign of neutropenia.

Pregnancy: Female patients of childbearing age should be told about the consequences of second- and third-trimester exposure to ACE inhibitors, and they should also be told that these consequences do not appear to have resulted from intrauterine ACE-inhibitor exposure that has been limited to the first trimester. These patients should be asked to report pregnancies to their physicians as soon as possible.

NOTE: As with many other drugs, certain advice to patients being treated with VASERETIC is warranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.

Drug Interactions: Enalapril Maleate; Hypotension—Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril. The possibility of hypotensive effects with enalapril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril. If it is necessary to continue the diuretic, provide medical supervision for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS.)

Agents Causing Renin Release: The antihypertensive effect of enalapril is augmented by antihypertensive agents that cause renin release (e.g., diuretics).

Other Cardiovascular Agents: Enalapril has been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine and prazosin without evidence of clinically significant adverse interactions.

Agents Increasing Serum Potassium: Enalapril attenuates diuretic-induced potassium loss. Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia they should be used with caution and with frequent monitoring of serum potassium.

Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. A few cases of lithium toxicity have been reported in patients receiving concomitant enalapril and lithium and were reversible upon discontinuation of both drugs. It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium. **Hydrochlorothiazide:** When administered concurrently the following drugs may interact with thiazide diuretics:

Alcohol, barbiturates, or narcotics—potentiation of orthostatic hypotension may occur.

Antidiabetic drugs (oral agents and insulin)—dosage adjustment of the antidiabetic drug may be required.

Other antihypertensive drugs—additive effect or potentiation.

Cholestyramine and colestipol resins—Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.

Corticosteroids, ACTH—intensified electrolyte depletion, particularly hypokalemia.

Pressor amines (e.g., norepinephrine)—possible decreased response to pressor amines but not sufficient to preclude their use.

Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine)—possible increased responsiveness to the muscle relaxant.

Lithium—should not generally be given with diuretics. Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity. Refer to the package insert for lithium preparations before use of such preparations with VASERETIC.

Non-steroidal Anti-inflammatory Drugs—In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. Therefore, when VASERETIC and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Enalapril in combination with hydrochlorothiazide was not mutagenic in the Ames microbial mutagen test with or without metabolic activation. Enalapril-hydrochlorothiazide did not produce DNA single strand breaks in an *in vitro* alkaline elution

* Registered trademark of Hospital Ltd.

assay in rat hepatocytes or chromosomal aberrations in an *in vivo* mouse bone marrow assay.

Enalapril Maleate: There was no evidence of a tumorigenic effect when enalapril was administered for 106 weeks to rats at doses up to 90 mg/kg/day (150 times* the maximum daily human dose). Enalapril has also been administered for 94 weeks to male and female mice at doses up to 90 and 180 mg/kg/day, respectively, (150 and 300 times* the maximum daily dose for humans) and showed no evidence of carcinogenicity.

Neither enalapril maleate nor the active diacid was mutagenic in the Ames microbial mutagen test with or without metabolic activation. Enalapril was also negative in the following genotoxicity studies: rec-assay, reverse mutation assay with *E. coli*, sister chromatid exchange with cultured mammalian cells, and the micronucleus test with mice, as well as in an *in vivo* cytogenetic study using mouse bone marrow.

There were no adverse effects on reproductive performance in male and female rats treated with 10 to 90 mg/kg/day of enalapril.

Hydrochlorothiazide: Two-year feeding studies in mice and rats conducted under the auspices of the National Toxicology Program (NTP) uncovered no evidence of a carcinogenic potential of hydrochlorothiazide in female mice (at doses of up to approximately 600 mg/kg/day) or in male and female rats (at doses of up to approximately 100 mg/kg/day). The NTP, however, found equivocal evidence for hepatocarcinogenicity in male mice.

Hydrochlorothiazide was not genotoxic *in vitro* in the Ames mutagenicity assay of *Salmonella typhimurium* strains TA 98, TA 100, TA 1535, TA 1537, and TA 1538 and in the Chinese Hamster Ovary (CHO) test for chromosomal aberrations, or *in vivo* in assays using mouse germinal cell chromosomes, Chinese hamster bone marrow chromosomes, and the *Drosophila* sex-linked recessive lethal trait gene. Positive test results were obtained only in the *in vitro* CHO Sister Chromatid Exchange (clastogenicity) and in the Mouse Lymphoma Cell (mutagenicity) assays, using concentrations of hydrochlorothiazide from 43 to 1300 mg/mL, and in the *Aspergillus nidulans* non-disjunction assay at an unspecified concentration.

Hydrochlorothiazide had no adverse effects on the fertility of mice and rats of either sex in studies wherein these species were exposed, via their diet, to doses of up to 100 and 4 mg/kg, respectively, prior to conception and throughout gestation.

Pregnancy: Pregnancy Categories C (first trimester) and D (second and third trimesters). See WARNINGS, Pregnancy, Enalapril Maleate, Fetal/Neonatal Morbidity and Mortality.

Nursing Mothers: Enalapril and enalaprilat are detected in human milk in trace amounts. Thiazides do appear in human milk. Because of the potential for serious reactions in nursing infants from either drug, a decision should be made whether to discontinue nursing or to discontinue VASERETIC, taking into account the importance of the drug to the mother.

Pediatric Use: Safety and effectiveness in children have not been established.

ADVERSE REACTIONS: VASERETIC has been evaluated for safety in more than 1500 patients, including over 300 patients treated for one year or more. In clinical trials with VASERETIC no adverse experiences peculiar to this combination drug have been observed. Adverse experiences that have occurred, have been limited to those that have been previously reported with enalapril or hydrochlorothiazide.

The most frequent clinical adverse experiences in controlled trials were: dizziness (8.6 percent), headache (5.5 percent), fatigue (3.9 percent) and cough (3.5 percent). Adverse experiences occurring in greater than two percent of patients treated with VASERETIC in controlled clinical trials were: muscle cramps (2.7 percent), nausea (2.5 percent), asthenia (2.4 percent), orthostatic effects (2.3 percent), impotence (2.2 percent), and diarrhea (2.1 percent).

Clinical adverse experiences occurring in 0.5 to 2.0 percent of patients in controlled trials included: **Body As A Whole:** Syncope, chest pain, abdominal pain; **Cardiovascular:** Orthostatic hypotension, palpitation, tachycardia; **Digestive:** Vomiting, dyspepsia, constipation, flatulence, dry mouth; **Nervous/Psychiatric:** Insomnia, nervousness, paresthesia, somnolence, vertigo; **Skin:** Pruritus, rash; **Other:** Dyspnea, gout, back pain, arthralgia, diaphoresis, decreased libido, tinnitus, urinary tract infection.

Angioedema: Angioedema has been reported in patients receiving VASERETIC (0.6 percent). Angioedema associated with laryngeal edema may be fatal. If angioedema of the face, extremities, lips, tongue, glottis and/or larynx occurs, treatment with VASERETIC should be discontinued and appropriate therapy instituted immediately. (See WARNINGS.)

Hypotension: In clinical trials, adverse effects relating to hypotension occurred as follows: hypotension (0.9 percent), orthostatic hypotension (1.5 percent), other orthostatic effects (2.3 percent). In addition syncope occurred in 1.3 percent of patients. (See WARNINGS.)

Cough: See PRECAUTIONS, Cough.

Clinical Laboratory Test Findings; Serum Electrolytes: See PRECAUTIONS.

Creatinine, Blood Urea Nitrogen: In controlled clinical trials minor increases in blood urea nitrogen and serum creatinine, reversible upon discontinuation of therapy, were observed in about 0.6 percent of patients with essential hypertension treated with VASERETIC. More marked increases have been reported in other enalapril experience. Increases are more likely to occur in patients with renal artery stenosis. (See PRECAUTIONS.)

Serum Uric Acid, Glucose, Magnesium, and Calcium: See PRECAUTIONS.

Hemoglobin and Hematocrit: Small decreases in hemoglobin and hematocrit (mean decreases of approximately 0.3 g percent and 1.0 vol percent, respectively) occur frequently in hypertensive patients treated with VASERETIC but are rarely of clinical importance unless another cause of anemia coexists. In clinical trials, less than 0.1 percent of patients discontinued therapy due to anemia.

Liver Function Tests: Rarely, elevations of liver enzymes and/or serum bilirubin have occurred.

Other adverse reactions that have been reported with the individual components are listed below and, within each category, are in order of decreasing severity.

Enalapril Maleate:—Enalapril has been evaluated for safety in more than 10,000 patients. In clinical trials adverse reactions which occurred with enalapril were also seen with VASERETIC. However, since enalapril has been marketed, the following adverse reactions have been reported: **Body As A Whole:** Anaphylactoid reactions (see PRECAUTIONS, Hemodialysis Patients); **Cardiovascular:** Cardiac arrest; myocardial infarction or cerebrovascular accident, possibly secondary to excessive hypotension in high risk patients (see WARNINGS, Hypotension); pulmonary embolism and infarction; pulmonary edema; rhythm disturbances including atrial tachycardia and bradycardia; atrial fibrillation; hypotension; angina pectoris; **Digestive:** Ileus, pancreatitis, hepatic failure, hepatitis (hepatocellular [proven on rechallenge] or cholestatic jaundice), melena, anorexia, glossitis, stomatitis, dry mouth; **Hematologic:** Rare cases of neutropenia, thrombocytopenia and bone marrow depression. Hemolytic anemia, including cases of hemolysis in patients with G-6-PD deficiency, has been reported; a causal relationship to enalapril has not been established. **Nervous System/Psychiatric:** Depression, confusion, ataxia, peripheral neuropathy (e.g., paresthesia, dysesthesia); **Urogenital:** Renal failure, oliguria, renal dysfunction (see PRECAUTIONS), flank pain, gynecomastia; **Respiratory:** Pulmonary infiltrates, bronchospasm, pneumonia, bronchitis, rhinorrhea, sore throat and hoarseness, asthma, upper respiratory infection; **Skin:** Exfoliative dermatitis, toxic epidermal necrolysis, Stevens-Johnson syndrome, herpes zoster, erythema multiforme, urticaria, pemphigus, alopecia, flushing, photosensitivity; **Special Senses:** Blurred vision, taste alteration, anosmia, conjunctivitis, dry eyes, tearing.

Miscellaneous: A symptom complex has been reported which may include a positive ANA, an elevated erythrocyte sedimentation rate, arthralgia/arthritis, myalgia/myositis, fever, serositis, vasculitis, leukocytosis, eosinophilia, photosensitivity, rash and other dermatologic manifestations.

Fetal/Neonatal Morbidity and Mortality: See WARNINGS, Pregnancy, Enalapril Maleate, Fetal/Neonatal Morbidity and Mortality.

Hydrochlorothiazide:—**Body as a Whole:** Weakness; **Digestive:** Pancreatitis, jaundice (intrahepatic cholestatic jaundice), sialadenitis, cramping, gastric irritation, anorexia; **Hematologic:** Aplastic anemia, agranulocytosis, leukopenia, hemolytic anemia, thrombocytopenia; **Hypersensitivity:** Purpura, photosensitivity, urticaria, necrotizing angitis (vasculitis and cutaneous vasculitis), fever, respiratory distress including pneumonitis and pulmonary edema, anaphylactic reactions; **Musculoskeletal:** Muscle spasm; **Nervous System/Psychiatric:** Restlessness; **Renal:** Renal failure, renal dysfunction, interstitial nephritis (see WARNINGS); **Skin:** Erythema multiforme including Stevens-Johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis, alopecia; **Special Senses:** Transient blurred vision, xanthopsia.

* Based on patient weight of 50 kg.

For more detailed information, consult your DuPont Pharma Representative or see Prescribing Information.

Dist. by

 **MERCK & CO., INC.**
West Point, PA 19486, USA

Issued August 1993
7432320

Printed in USA

THE JULY CALIFORNIA PHYSICIAN BRINGS YOU . . .

FEATURE ARTICLES:

Lonnie Bristow, MD: Ready To Lead, To Fight, To Unite. In an exclusive *California Physician* interview, AMA's new President-Elect discusses past victories for patients and public health, and current battles for organized medicine.

By Aura Bland

The Profiteering of HMOs. CMA's study scrutinizes how for-profit conversions have directed premium dollars into profits, and Sacramento staff also outlines reform efforts in the Legislature.

By Steve Thompson and
Zabrae Valentine

A Guide to Physician Disciplinary Hearings. An attorney advises physicians on how to present the best defense before hospital disciplinary committees.

By Brock D. Phillips, JD

Ten Minutes With . . . Gov. Howard Dean, MD. Discussing his state health system financing bills creation, alteration, and setbacks, the Vermont physician governor presents some lessons for health system reform.

By Trish Beall

CP Reports, including:

Blue Cross must establish \$1 billion charity foundation . . . CMA Board moves managed care organization

forward . . . Sonoma County MDS appear on bilingual radio show . . . Getting to know more CMA trustees

and our regular columns and departments

Invest a stamp



Save a bundle

For the price of a stamp, you can get the latest edition of the federal government's free **Consumer Information Catalog** listing more than 200 free or low-cost government publications on topics such as federal benefits, jobs, health, housing, education, cars, and much more. Our booklets will help you save money, make money, and spend it a little more wisely.

So stamp out ignorance, and write today for the latest free **Catalog**. Send your name and address to:

**Consumer Information Center
Department SB
Pueblo, Colorado 81009**

A public service of this publication and the Consumer Information Center of the U.S. General Services Administration.

YOCON[®] YOHIMBINE HCl

Description: Yohimbine is a 3a-15a-20B-17a-hydroxy Yohimbine-16a-carboxylic acid methyl ester. The alkaloid is found in Rubiaceae and related trees. Also in Rauwolfia Serpentina (L) Benth. Yohimbine is an indolalkylamine alkaloid with chemical similarity to reserpine. It is a crystalline powder, odorless. Each compressed tablet contains (1/12 gr.) 5.4 mg of Yohimbine Hydrochloride.

Action: Yohimbine blocks presynaptic alpha-2 adrenergic receptors. Its action on peripheral blood vessels resembles that of reserpine, though it is weaker and of short duration. Yohimbine's peripheral autonomic nervous system effect is to increase parasympathetic (cholinergic) and decrease sympathetic (adrenergic) activity. It is to be noted that in male sexual performance, erection is linked to cholinergic activity and to alpha-2 adrenergic blockade which may theoretically result in increased penile inflow, decreased penile outflow or both.

Yohimbine exerts a stimulating action on the mood and may increase anxiety. Such actions have not been adequately studied or related to dosage although they appear to require high doses of the drug. Yohimbine has a mild anti-diuretic action, probably via stimulation of hypothalamic centers and release of posterior pituitary hormone.

Reportedly, Yohimbine exerts no significant influence on cardiac stimulation and other effects mediated by B-adrenergic receptors. Its effect on blood pressure, if any, would be to lower it; however no adequate studies are at hand to quantitate this effect in terms of Yohimbine dosage.

Indications: Yocon[®] is indicated as a sympatholytic and mydriatic. It may have activity as an aphrodisiac.

Contraindications: Renal diseases, and patient's sensitive to the drug. In view of the limited and inadequate information at hand, no precise tabulation can be offered of additional contraindications.

Warning: Generally, this drug is not proposed for use in females and certainly must not be used during pregnancy. Neither is this drug proposed for use in pediatric, geriatric or cardio-renal patients with gastric or duodenal ulcer history. Nor should it be used in conjunction with mood-modifying drugs such as antidepressants, or in psychiatric patients in general.

Adverse Reactions: Yohimbine readily penetrates the (CNS) and produces a complex pattern of responses in lower doses than required to produce peripheral alpha-adrenergic blockade. These include, anti-diuresis, a general picture of central excitation including elevation of blood pressure and heart rate, increased motor activity, irritability and tremor. Sweating, nausea and vomiting are common after parenteral administration of the drug.^{1,2} Also dizziness, headache, skin flushing reported when used orally.^{1,3}


Dosage and Administration: Experimental dosage reported in treatment of erectile impotence.^{1,3,4} 1 tablet (5.4 mg) 3 times a day, to adult males taken orally. Occasional side effects reported with this dosage are nausea, dizziness or nervousness. In the event of side effects dosage to be reduced to 1/2 tablet 3 times a day, followed by gradual increases to 1 tablet 3 times a day. Reported therapy not more than 10 weeks.³

How Supplied: Oral tablets of YOCON[®] 1/12 gr. 5.4mg in bottles of 100's NDC 53159-001-01, 1000's NDC 53159-001-10 and Blister-Paks of 30's NDC 53159-001-30

References:

1. A. Morales et al., New England Journal of Medicine: 1221, November 12, 1981.
2. Goodman, Gilman — The Pharmacological basis of Therapeutics 6th ed., p. 176-188. McMillan December Rev. 1/85.
3. Weekly Urological Clinical Letter, 27:2, July 4, 1983.
4. A. Morales et al., The Journal of Urology 128: 45-47, 1982.

Rev. 1/85



Available at pharmacies nationwide

**PALISADES
PHARMACEUTICALS, INC.**
64 North Summit Street
Tenafly, New Jersey 07670
(201) 569-8502
(800) 237-9083

QD STAYING POWER

Positron emission tomography (PET) image of ^{11}C -triamcinolone acetonide following intranasal administration of Nasacort[®]

ONCE DAILY[®]
Nasacort[®]
(triamcinolone acetonide) Nasal Inhaler



***Provides comfortable, prompt relief
of allergic rhinitis and effective QD dosing***

- Nasacort remains in the nasal mucosa with no measurable effect on HPA function^{1,3*}

Duration of acquisition of the PET image was approximately 55 minutes due to ^{11}C decay ($t_{1/2}$ of 20 minutes).¹ (n=2)

- Nasacort provides prompt relief for many patients — symptom reduction may occur as soon as 24 hours after starting therapy⁴
- Nasacort provides effective QD dosing — 2 puffs/nostril/day effectively controls symptoms in most patients; however, QD dosing can be increased to 4 puffs/nostril/day when necessary

Please see brief summary of prescribing information on adjacent page.

* In doses up to 440 mcg/day.³

Nasacort...Once Is Enough

QD STAYING POWER

ONCE DAILY
Nasacort[®]
(triamcinolone acetonide)
Nasal Inhaler

Nasacort...Once Is Enough

ONCE DAILY
Nasacort[®]
(triamcinolone acetonide)
Nasal Inhaler

For Intranasal Use Only
Shake Well Before Using

BRIEF SUMMARY

CONTRAINDICATIONS: Hypersensitivity to any of the ingredients of this preparation contraindicates its use.

WARNINGS: The replacement of a systemic corticosteroid with a topical corticoid can be accompanied by signs of adrenal insufficiency and, in addition, some patients may experience symptoms of withdrawal, e.g., joint and/or muscular pain, lassitude and depression. Patients previously treated for prolonged periods with systemic corticosteroids and transferred to topical corticoids should be carefully monitored for acute adrenal insufficiency in response to stress. In those patients who have asthma or other clinical conditions requiring long-term systemic corticosteroid treatment, too rapid a decrease in systemic corticosteroids may cause a severe exacerbation of their symptoms.

Children who are on immunosuppressant drugs are more susceptible to infections than healthy children. Chickenpox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant doses of corticosteroids. In such children, or in adults who have not had these diseases, particular care should be taken to avoid exposure. If exposed, therapy with varicella zoster immune globulin (VZIG) or pooled intravenous immunoglobulin (IVIG), as appropriate, may be indicated. If chickenpox develops, treatment with antiviral agents may be considered.

The use of Nasacort Nasal Inhaler with alternate-day systemic prednisone could increase the likelihood of hypothalamic-pituitary-adrenal (HPA) suppression compared to a therapeutic dose of either one alone. Therefore, Nasacort Nasal Inhaler should be used with caution in patients already receiving alternate-day prednisone treatment for any disease.

PRECAUTIONS

General: In clinical studies with triamcinolone acetonide administered intranasally, the development of localized infections of the nose and pharynx with *Candida albicans* has rarely occurred. When such an infection develops it may require treatment with appropriate local therapy and discontinuance of treatment with Nasacort Nasal Inhaler.

Triamcinolone acetonide administered intranasally has been shown to be absorbed into the systemic circulation in humans. Patients with active rhinitis showed absorption similar to that found in normal volunteers. Nasacort at 440 mcg/day for 42 days did not measurably affect adrenal response to a six hour cosyntropin test. In the same study prednisone 10 mg/day significantly reduced adrenal response to ACTH over the same period (see CLINICAL TRIALS section).

Nasacort Nasal Inhaler should be used with caution, if at all, in patients with active or quiescent tuberculous infections of the respiratory tract or in patients with untreated fungal, bacterial, or systemic viral infections or ocular herpes simplex.

Because of the inhibitory effect of corticosteroids on wound healing in patients who have experienced recent nasal septal ulcers, nasal surgery or trauma, a corticosteroid should be used with caution until healing has occurred. As with other nasally inhaled corticosteroids, nasal septal perforations have been reported in rare instances.

When used at excessive doses, systemic corticosteroid effects such as hypercorticism and adrenal suppression may appear. If such changes occur, Nasacort Nasal Inhaler should be discontinued slowly, consistent with accepted procedures for discontinuing oral steroid therapy.

Information for Patients: Patients being treated with Nasacort Nasal Inhaler should receive the following information and instructions.

Patients who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles and, if exposed, to obtain medical advice.

Patients should use Nasacort Nasal Inhaler at regular intervals since its effectiveness depends on its regular use. A decrease in symptoms may occur as soon as 12 hours after starting steroid therapy and generally can be expected to occur within a few days of initiating therapy in allergic rhinitis. The patient should take the medication as directed and should not exceed the prescribed dosage. The patient should contact the physician if symptoms do not improve after three weeks, or if the condition worsens. Nasal irritation and/or burning or stinging after use of the spray occur only rarely with this product. The patient should contact the physician if they occur.

For the proper use of this unit and to attain maximum improvement, the patient should read and follow the accompanying patient instructions carefully. Because the amount dispensed per puff may not be consistent, it is important to shake the canister well. Also, the canister should be discarded after 100 actuations.

Carcinogenesis, Mutagenesis: Animal studies of triamcinolone acetonide to test its carcinogenic potential are underway.

Impairment of Fertility: Male and female rats which were administered oral triamcinolone acetonide at doses as high as 15 mcg/kg/day (110 mcg/m²/day, as calculated on a surface area basis) exhibited no evidence of impaired fertility. The maximum human dose, for comparison, is 6.3 mcg/kg/day (240 mcg/m²/day). However, a few female rats which received maternally toxic doses of 8 or 15 mcg/kg/day (60 mcg/m²/day or 110 mcg/m²/day, respectively, as calculated on a

surface area basis) exhibited dystocia and prolonged delivery. Developmental toxicity, which included increases in fetal resorptions and stillbirths and decreases in pup body weight and survival, also occurred at the maternally toxic doses (2.5 - 15.0 mcg/kg/day or 20 - 110 mcg/m²/day, as calculated on a surface area basis). Reproductive performance of female rats and effects on fetuses and offspring were comparable between groups that received placebo and non-toxic or marginally toxic doses (0.5 and 1.0 mcg/kg/day or 3.8 mcg/m²/day and 7.0 mcg/m²/day).

Pregnancy: Pregnancy Category C. Like other corticoids, triamcinolone acetonide has been shown to be teratogenic in rats and rabbits. Teratogenic effects, which occurred in both species at 0.02, 0.04 and 0.08 mg/kg/day (approximately 135, 270 and 540 mcg/m²/day in the rat and 320, 640 and 1280 mcg/m²/day in the rabbit, as calculated on a surface area basis), included a low incidence of cleft palate and/or internal hydrocephaly and axial skeletal defects. Teratogenic effects, including CNS and cranial malformations, have also been observed in non-human primates at 0.5 mg/kg/day (approximately 6.7 mg/m²/day). The doses of 0.02, 0.04, 0.08, and 0.5 mg/kg/day used in these toxicology studies are approximately 12.8, 25.5, 51, and 318.7 times the minimum recommended dose of 110 mcg of Nasacort per day and 3.2, 6.4, 12.7, and 80 times the maximum recommended dose of 440 mcg of Nasacort per day based on a patient body weight of 70 kg. Administration of aerosol by inhalation to pregnant rats and rabbits produced embryotoxic and fetotoxic effects which were comparable to those produced by administration by other routes. There are no adequate and well-controlled studies in pregnant women. Triamcinolone acetonide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Experience with oral corticoids since their introduction in pharmacologic as opposed to physiologic doses suggests that rodents are more prone to teratogenic effects from corticoids than humans. In addition, because there is a natural increase in glucocorticoid production during pregnancy, most women will require a lower exogenous steroid dose and many will not need corticoid treatment during pregnancy.

Nonteratogenic Effects: Hypoadrenalism may occur in infants born of mothers receiving corticosteroids during pregnancy. Such infants should be carefully observed.

Nursing Mothers: It is not known whether triamcinolone acetonide is excreted in human milk. Because other corticosteroids are excreted in human milk, caution should be exercised when Nasacort Nasal Inhaler is administered to nursing women.

Pediatric Use: Safety and effectiveness have not been established in children below the age of 12. Oral corticoids have been shown to cause growth suppression in children and teenagers, particularly with higher doses over extended periods. If a child or teenager on any corticoid appears to have growth suppression, the possibility that they are particularly sensitive to this effect of steroids should be considered.

ADVERSE REACTIONS: In controlled and uncontrolled studies, 1257 patients received treatment with intranasal triamcinolone acetonide. Adverse reactions are based on the 567 patients who received a product similar to the marketed Nasacort canister. These patients were treated for an average of 48 days (range 1 to 117 days). The 145 patients enrolled in uncontrolled studies received treatment from 1 to 820 days (average 332 days).

The most prevalent adverse experience was headache, being reported by approximately 18% of the patients who received Nasacort. Nasal irritation was reported by 2.8% of the patients receiving Nasacort. Other nasopharyngeal side effects were reported by fewer than 5% of the patients who received Nasacort and included: dry mucous membranes, naso-sinus congestion, throat discomfort, sneezing, and epistaxis. The complaints do not usually interfere with treatment and in the controlled and uncontrolled studies approximately 1% of patients have discontinued because of these nasal adverse effects.

In the event of accidental overdose, an increased potential for these adverse experiences may be expected, but systemic adverse experiences are unlikely (see OVERDOSAGE section).

OVERDOSAGE: Acute overdosage with this dosage form is unlikely. The acute topical application of the entire 15 mg of the canister would most likely cause nasal irritation and headache. It would be unlikely to see acute systemic adverse effects if the nasal application of the 15 mg of triamcinolone acetonide was administered all at once.

Caution: Federal (U.S.A.) law prohibits dispensing without prescription. Please see product circular for full prescribing information.

REFERENCES:

1. Data on file, Rhône-Poulenc Rorer Pharmaceuticals Inc.
2. Ziemniak JA: Pharmacokinetics of intranasal triamcinolone acetonide. *J Respir Dis* 1991;12 (3, Suppl):S41-S42.
3. Feiss G, Morris R, Rom D, et al: A comparative study of the effects of intranasal triamcinolone acetonide aerosol (ITAA) and prednisone on adrenocortical function. *J Allergy Clin Immunol* 1992;89:1151-1156.
4. Findlay S, Huber F, Garcia J, et al: Efficacy of once-a-day intranasal administration of triamcinolone acetonide in patients with seasonal allergic rhinitis. *Ann Allergy* 1992;68(3):228-232.



Marketed by:

RHÔNE-POULENC RORER

RHÔNE-POULENC RORER PHARMACEUTICALS INC.

560 ARCOLA ROAD
COLLEGEVILLE, PA 19426

Innovators in Respiratory Care

NA06L794(7357B) 7/94 FC#94-F08 ©1994 Rhône-Poulenc Rorer Pharmaceuticals Inc. Printed in U.S.A.

Physicians and their immediate family members can receive preferential treatment in mortgage financing!

The AMA-Sponsored Home Mortgage Program is provided exclusively by Prudential Home Mortgage and offers physicians special features such as:

- Loan commitment* before you begin searching for a home that can improve your bargaining power with sellers
- Low down payment programs
- Zero point option
- Fast loan decisions, often within 24 hours**
- Full refund of appraisal cost after closing
- Competitive rates on a wide variety of mortgage products
- Toll-free application process
- No-cost 60 day interest rate lock

Just call...1-800-443-8877

Mortgage counselors are available to assist you from 5 a.m. to 9 p.m. (Pacific time) Monday through Friday.



Prudential Home Mortgage 

*Your loan commitment will be subject to the terms and conditions stated in your commitment letter for this program.

**Eligibility requirements for the 24 hour loan decision include: Single family dwelling only, with a \$500,000 maximum loan amount. Condos, co-ops, second homes and investment properties are excluded. Also, because your loan decision is not subject to an appraisal, you may want to consult your legal advisor to include an appraisal contingency in your purchase contract. Other conditions may apply.

© 1994 The Prudential Insurance Company of America. All loans are originated by The Prudential Home Mortgage Company, Inc. The Prudential Home Mortgage Company, Inc., 8000 Maryland Avenue, Clayton, Missouri, is an affiliate of The Prudential Insurance Company of America, doing business as P.H. Mortgage Company, Inc. in Ohio. New York Office: Expressway Executive Center, Inc., Suite 100, 48 South Service Road, Melville, New York 11747; Arizona BK 8408; Florida Licensed Mortgage Lender; Illinois Residential Mortgage Licensee; Licensed Mortgage Banker/New Jersey Department of Banking; Calif. Broker/Lender. All California loans will be made pursuant to a California Department of Corporations Consumer Finance Lender license or Commercial Finance Lender license. Equal Housing Opportunity.

MEMORIAL/UCI CENTER FOR HEALTH EDUCATION

AUGUST, 1994

3rd Internal Medicine Board Review
August 8-12, 1994
NEWPORT BEACH, CALIFORNIA

SEPTEMBER, 1994

2nd International Symposium on the
Difficult Airway
September 16-18, 1994
NEWPORT BEACH, CALIFORNIA

7th Annual Advanced OB/GYN & Transvaginal Ultrasound

September 29, 1994–October 1, 1994
ORANGE, CALIFORNIA

OCTOBER, 1994

Primary Care—1994
October 11-14, 1994
LANAI, HAWAII

Pediatrics for the Practitioner

October 17-20, 1994
ISLAND OF HAWAII

Update Clinical Medicine

October 17-20, 1994
ISLAND OF HAWAII

NOVEMBER, 1994

5th Annual Practical Methods in
Diabetes Management
November 11-12, 1994
COSTA MESA, CALIFORNIA

Current Issues in Perinatal Medicine

November 11-13, 1994
RANCHO MIRAGE, CALIFORNIA

17th Annual OB/GYN Review Course

November 14-19, 1994
COSTA MESA, CALIFORNIA

DECEMBER, 1994

Laser Bronchoscopy, Stents, Brachytherapy & Thoracoscopy for the Pulmonologist

December 1-3, 1994
LONG BEACH, CALIFORNIA



**UNIVERSITY OF
CALIFORNIA,
IRVINE**

**CENTER FOR
HEALTH
EDUCATION**

LONG BEACH, CALIFORNIA

For further information contact
the Center for Health Education
☎ Offices at (310) 933-3811.

Sponsored by
the University of California, Irvine,
College of Medicine in conjunction
with Memorial/UCI Center for
Health Education.

CME CREDITS VARY PER COURSE.

COMMITTED TO EXCELLENCE

The logo is a circular emblem. At the top, within a small hexagon, is the word "Roche". Below this, the words "PRESIDENT'S ACHIEVEMENT AWARD" are written in a bold, sans-serif font, stacked vertically.

ROCHE LABORATORIES

presents the winners of the 1993 President's Achievement Award


Please join us in honoring these outstanding Roche representatives who have distinguished themselves by a truly exceptional level of professionalism, performance and dedication to quality health care. Throughout the year, each of these award-winning individuals has consistently exemplified the Roche Commitment to Excellence and we're proud to invite you to share in congratulating them on their achievement.



*Jerry Parkinson
Idaho Falls, Idaho*



*Pauline Gill
Salt Lake City, Utah*




*Scott Sarisky
Mesa, Arizona*



*Suellen White
Mesa, Arizona*




*Tim Hutsko
Phoenix, Arizona*



*Rob Battenschlag
Seattle, Washington*



*Tony Ochoa
Vancouver, Washington*



*Robert Posch
Seattle, Washington*

PRO TECTION

MALPRACTICE COVERAGE AT ITS BEST


- Effective and experienced management.
- An improved cash flow position immediately.
- \$1 million per occurrence/\$3 million aggregate per year.
- Affordable retroactive coverage.
- Remedial medical services designed to alleviate adverse medical/surgical results.

COMPARE AND SAVE

For further information, please call or write:

PHYSICIANS
I N T E R I N D E M N I T Y

541 West Colorado Street, Glendale, California 91204
(818) 241-5119



and
The Department of
Physician Education Services
present

The 2nd Annual
**ADVANCES IN CLINICAL
NEUROSCIENCES
SYMPOSIUM**

Saturday and Sunday,
November 19-20, 1994

MARRIOTT'S RANCHO LAS PALMAS RESORT
RANCHO MIRAGE, CALIFORNIA

Save the Date!

This symposium provides an overview of clinical issues, techniques and advances in treatment of several diseases of the nervous system
Audience: primary care physicians, internists, neurologists, neurosurgeons, oncologists, radiation oncologists and radiologists.

PARKINSON'S DISEASE

KRIS S. BANKIEWICZ, M.D., *Somatix Therapy Corp., Alameda*
MICHAEL DOGALI, M.D., *New York University*
DEANE B. (SKIP) JACQUES, M.D., *The Neurosciences Institute, Good Samaritan, Los Angeles*
OLEG V. KOPYOV, M.D., PH.D., *The Neurosciences Institute, Good Samaritan, Los Angeles*
ABRAHAM N. LIEBERMAN, M.D., *Barrows Neurological Institute, Phoenix, The Neurosciences Institute, Good Samaritan, Los Angeles*
IGNACIO N. MADRAZO, M.D., *Mexico City, Mexico*
BARRY SNOW, M.D., *University of British Columbia*

STEREOTACTIC GAMMA KNIFE RADIOSURGERY

CHRISTOPHER M. DUMA, M.D., *The Neurosciences Institute, Good Samaritan, Los Angeles*
DOUGLAS KONDZIOLKA, M.D., *University of Pittsburgh*
EDWARD R. LAWS, M.D., *University of Virginia*
RONALD YOUNG, M.D., *Northwest Hospital, Seattle*

BRAIN TUMORS

GALE A. GRANGER, PH.D., *University of California, Irvine, The Neurosciences Institute, Good Samaritan, Los Angeles*
RANDALL E. MERCHANT, PH.D., *Virginia Commonwealth University, The Medical College of Virginia*

10 hours of Category I CME credit

For information and registration phone 800-762-1692.

Get the Facts From CMA Attorneys

Announcing The Physician's Managed Care Manual


NEW!

Explains what physicians should know about a plan before signing.

- How can you determine whether a capitated payment will be adequate?
- Will your risk sharing arrangement put you at too much risk?
- How do you prevent an IPA or PPO from signing undesirable contracts on their behalf?

Other topics discussed include:

- Financial incentives • Contract amendment negotiation • Risk sharing arrangements
- Insolvent plans • Capitation issues for specialists
- Verification of coverage • What to do when necessary care is denied
- Point-of-service plans • Termination without cause and much more...



When you order the **Physician's Managed Care Manual** you will receive FREE a copy of the California Medical Association's **Summary of California HMO Laws Affecting Physicians**

Mail check or credit information to: California Medical Association, Publications Department, P.O. Box 7690, San Francisco, CA 94120-7690 or call 415/882-5175 (all orders must be pre-paid and include sales tax).

Price: \$50 CMA members, \$100 non-members.

Consult Hundreds of Specialists With One Call

USC Physician Access and
Communication Exchange
is sponsored by
USC University Hospital,
Childrens Hospital Los Angeles,
The Doheny Eye Institute
and USC/Norris Comprehensive
Cancer Center.
USC PACE is designed
exclusively for use
by physicians and their
office staffs.



1.800.ASK.PACE

PROGRAM PROFILE

THE SWALLOWING CENTER

At the Swallowing Center at USC University Hospital, advanced diagnostic capabilities allow specialists to determine if patients with reflux disease are benefiting from medication, or if surgical interventions would be more appropriate. By receiving an accurate diagnosis in a timely fashion, patients may avoid the ravages of end-stage disease that have been associated with long-term medication.


Sophisticated Diagnoses

Patients at the Center undergo a comprehensive history and physical examination, and a series of sophisticated diagnostic evaluations. These may include esophageal manometry, video esophagram, nasopharyngeal and esophageal endoscopy, quantitative radionuclide gastric and esophageal scanning, and ambulatory motility, 24-hour pH, bile probe, and gastric emptying tests.

Esophageal manometry measures and records the muscle function of the esophagus. These studies are particularly detailed at the Swallowing Center, allowing for easy identification of abnormalities. Video esophagrams are used to visually assess the oropharyngeal, pharyngoesophageal and esophageal phases of swallowing. With this test, specialists see each swallowing motion as it occurs.

Multidisciplinary Approach to Swallowing Problems

This diagnostic expertise represents one of the many unique strengths that distinguishes the Swallowing Center at USC University Hospital. Another strength is its multidisciplinary approach: The Center's specialists include gastroenterologists, neurologists, general surgeons, otolaryngologists, pathologists, speech pathologists, radiologists and thoracic specialists.



USC University Hospital

University of Southern California

Treating Swallowing Disorders

The Swallowing Center evaluates and treats the full spectrum of swallowing disorders, including gastroesophageal reflux, esophageal strictures, diverticular of the esophagus, gastroparesis and scleroderma. Patients are referred for evaluation and treatment of:

- reflux disease refractory to medical therapy,
- symptoms whose etiology cannot be identified,
- swallowing disorders caused by neurologic dysfunction, Zenker's diverticulum or cricopharyngeal muscle dysfunction.

The Center has a particular interest in Barrett's esophagus, duodenal gastric reflux and complicated re-operations.

Innovative Surgical Approaches

The Center offers innovative treatment options to those patients with reflux disease or abnormalities of the peristaltic muscular contractions of the esophagus. These include balloon dilation and esophageal myotomy in which the muscular wall of the esophagus is divided, reducing the strength of esophageal contractions and turning swallowing into a gravity system.

The Nissen fundoplication procedure is done for patients with a defective lower esophageal sphincter through which acid gastric juice regurgitates. In this procedure, the surgeon augments the lower esophageal sphincter function by using the stomach muscle to reconstruct a new sphincter. The Center is also involved in endoscopic antireflux repair, utilizing scopes inserted into the inflated stomach orally and transcutaneously.

Close Contact With Referring Physicians

Specialists at the Swallowing Center are dedicated to maintaining close contact and frequent communication with referring physicians throughout the United States.

The Swallowing Center Co-Directors



Tom R. DeMeester, M.D., professor and chairman, Department of Surgery at the University of Southern California School of Medicine, earned his medical degree from the University of Michigan, Ann Arbor, and received

his surgical training at The Johns Hopkins Hospital in Baltimore. After a tour of military duty, Dr. DeMeester joined the faculty of the University of Chicago as Chief of Thoracic Surgery, a position he held for 10 years. He then served as Chairman of Surgery at Creighton University School of Medicine in Omaha, Nebraska. Dr. DeMeester joined USC in 1990.



Cedric G. Bremner, M.D., professor of Clinical Surgery and director of Clinical Research at USC, received his medical training at the University of the Witwatersrand in Johannesburg, South Africa, and spent

five years at the Royal Postgraduate Medical School and the Hammersmith Hospital in London doing postgraduate studies. He also did his F.R.C.S. in England and Edinburgh, Scotland before returning to Johannesburg and becoming a staff member of the University Medical School. He spent a year at the Mayo Clinic and in 1979 was promoted to full professor of the University of Johannesburg. He joined USC in 1993.



CONTINUING MEDICAL EDUCATION CALENDAR

The Southern Medical Association is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

JULY 18-21, 1994

FOCUS ON THE FEMALE PATIENT

LOCATION: Kiawah Island Resort, SC

SPECIALTY: OB/Gyn, Primary Care

CME CREDIT: AMA Category 1

FEE: SMA Members \$350; Non-Members \$475;
Non-Physicians \$225

JULY 29-31, 1994

PEDIATRICS AND ADOLESCENT MEDICINE

LOCATION: Sea Island, Georgia

SPECIALTY: Primary Care

CME CREDIT: AMA Category 1 - 15 hours

AAFP Prescribed - 15 hours

AOA Category 2-A - 15 hours

FEE: SMA Member \$310; Non-member \$435; Non-Physician \$225

JULY 22-24, 1994

FOCUS ON THE MALE PATIENT

LOCATION: Kiawah Island Resort, SC

SPECIALTY: Primary Care

CME CREDIT: AMA Category 1

FEE: SMA Member \$310; Non-member \$435;
Non-Physician \$225

AUGUST 12-14, 1994

MUSCULOSKELETAL PROBLEMS IN PRIMARY CARE

LOCATION: Naples, Florida

SPECIALTY: Primary Care

CME CREDIT: AMA Category 1

FEE: SMA Member \$295; Non-member \$420; Non-Physician \$200

JULY 24-27, 1994

GENERAL SURGERY

LOCATION: Sea Island, Georgia

SPECIALTY: Surgery

CME CREDIT: AMA Category 1

FEE: SMA Member \$475; Non-member \$600; Non-Physician \$300

AUGUST 19-21, 1994

SOUTHERN ORTHOPAEDIC ASSOCIATION ANNUAL MEETING

LOCATION: Bermuda

SPECIALTY: Orthopaedic and Traumatic Surgery

CME CREDIT: AMA Category 1

FEE: SOA Member \$400; Non-member \$550

JULY 28-30, 1994

SOUTHERN ASSOCIATION FOR ONCOLOGY ANNUAL MEETING

LOCATION: Jekyll Island, Georgia

SPECIALTY: Oncology

CME CREDIT: AMA Category 1

FEE: SAO Member \$400; Non-member \$550

*For more information, call Michelle Williamson,
Southern Medical Association, 800-423-4992 or 205-945-1840—TODAY!*

QD STAYING POWER

ONCE DAILY®
Nasacort Nasal Inhaler
(triamcinolone acetonide)

Nasacort...Once Is Enough

ONCE DAILY®
Nasacort Nasal Inhaler
(triamcinolone acetonide)

For Intranasal Use Only
Shake Well Before Using

BRIEF SUMMARY

CONTRAINDICATIONS: Hypersensitivity to any of the ingredients of this preparation contraindicates its use.

WARNINGS: The replacement of a systemic corticosteroid with a topical corticoid can be accompanied by signs of adrenal insufficiency and, in addition, some patients may experience symptoms of withdrawal, e.g., joint and/or muscular pain, lassitude and depression. Patients previously treated for prolonged periods with systemic corticosteroids and transferred to topical corticoids should be carefully monitored for acute adrenal insufficiency in response to stress. In those patients who have asthma or other clinical conditions requiring long-term systemic corticosteroid treatment, too rapid a decrease in systemic corticosteroids may cause a severe exacerbation of their symptoms.

Children who are on immunosuppressant drugs are more susceptible to infections than healthy children. Chickenpox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant doses of corticosteroids. In such children, or in adults who have not had these diseases, particular care should be taken to avoid exposure. If exposed, therapy with varicella zoster immune globulin (VZIG) or pooled intravenous immunoglobulin (IVIG), as appropriate, may be indicated. If chickenpox develops, treatment with antiviral agents may be considered.

The use of Nasacort Nasal Inhaler with alternate-day systemic prednisone could increase the likelihood of hypothalamic-pituitary-adrenal (HPA) suppression compared to a therapeutic dose of either one alone. Therefore, Nasacort Nasal Inhaler should be used with caution in patients already receiving alternate-day prednisone treatment for any disease.

PRECAUTIONS

General: In clinical studies with triamcinolone acetonide administered intranasally, the development of localized infections of the nose and pharynx with *Candida albicans* has rarely occurred. When such an infection develops it may require treatment with appropriate local therapy and discontinuance of treatment with Nasacort Nasal Inhaler.

Triamcinolone acetonide administered intranasally has been shown to be absorbed into the systemic circulation in humans. Patients with active rhinitis showed absorption similar to that found in normal volunteers. Nasacort at 440 mcg/day for 42 days did not measurably affect adrenal response to a six hour cosyntropin test. In the same study prednisone 10 mg/day significantly reduced adrenal response to ACTH over the same period (see CLINICAL TRIALS section).

Nasacort Nasal Inhaler should be used with caution, if at all, in patients with active or quiescent tuberculous infections of the respiratory tract or in patients with untreated fungal, bacterial, or systemic viral infections or ocular herpes simplex.

Because of the inhibitory effect of corticosteroids on wound healing in patients who have experienced recent nasal septal ulcers, nasal surgery or trauma, a corticosteroid should be used with caution until healing has occurred. As with other nasally inhaled corticosteroids, nasal septal perforations have been reported in rare instances.

When used at excessive doses, systemic corticosteroid effects such as hypercorticism and adrenal suppression may appear. If such changes occur, Nasacort Nasal Inhaler should be discontinued slowly, consistent with accepted procedures for discontinuing oral steroid therapy.

Information for Patients: Patients being treated with Nasacort Nasal Inhaler should receive the following information and instructions.

Patients who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles and, if exposed, to obtain medical advice.

Patients should use Nasacort Nasal Inhaler at regular intervals since its effectiveness depends on its regular use. A decrease in symptoms may occur as soon as 12 hours after starting steroid therapy and generally can be expected to occur within a few days of initiating therapy in allergic rhinitis. The patient should take the medication as directed and should not exceed the prescribed dosage. The patient should contact the physician if symptoms do not improve after three weeks, or if the condition worsens. Nasal irritation and/or burning or stinging after use of the spray occur only rarely with this product. The patient should contact the physician if they occur.

For the proper use of this unit and to attain maximum improvement, the patient should read and follow the accompanying patient instructions carefully. Because the amount dispensed per puff may not be consistent, it is important to shake the canister well. Also, the canister should be discarded after 100 actuations.

Carcinogenesis, Mutagenesis: Animal studies of triamcinolone acetonide to test its carcinogenic potential are underway.

Impairment of Fertility: Male and female rats which were administered oral triamcinolone acetonide at doses as high as 15 mcg/kg/day (110 mcg/m²/day, as calculated on a surface area basis) exhibited no evidence of impaired fertility. The maximum human dose, for comparison, is 6.3 mcg/kg/day (240 mcg/m²/day). However, a few female rats which received maternally toxic doses of 8 or 15 mcg/kg/day (60 mcg/m²/day or 110 mcg/m²/day, respectively, as calculated on a

surface area basis) exhibited dystocia and prolonged delivery. Developmental toxicity, which included increases in fetal resorptions and stillbirths and decreases in pup body weight and survival, also occurred at the maternally toxic doses (2.5 - 15.0 mcg/kg/day or 20 - 110 mcg/m²/day, as calculated on a surface area basis). Reproductive performance of female rats and effects on fetuses and offspring were comparable between groups that received placebo and non-toxic or marginally toxic doses (0.5 and 1.0 mcg/kg/day or 3.8 mcg/m²/day and 7.0 mcg/m²/day).

Pregnancy: Pregnancy Category C. Like other corticoids, triamcinolone acetonide has been shown to be teratogenic in rats and rabbits. Teratogenic effects, which occurred in both species at 0.02, 0.04 and 0.08 mcg/kg/day (approximately 135, 270 and 540 mcg/m²/day in the rat and 320, 640 and 1280 mcg/m²/day in the rabbit, as calculated on a surface area basis), included a low incidence of cleft palate and/or internal hydrocephaly and axial skeletal defects. Teratogenic effects, including CNS and cranial malformations, have also been observed in non-human primates at 0.5 mcg/kg/day (approximately 6.7 mcg/m²/day). The doses of 0.02, 0.04, 0.08, and 0.5 mcg/kg/day used in these toxicology studies are approximately 12.8, 25.5, 51, and 318.7 times the minimum recommended dose of 110 mcg of Nasacort per day based on a patient body weight of 70 kg. Administration of aerosol by inhalation to pregnant rats and rabbits produced embryotoxic and fetotoxic effects which were comparable to those produced by administration by other routes. There are no adequate and well-controlled studies in pregnant women. Triamcinolone acetonide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Experience with oral corticoids since their introduction in pharmacologic as opposed to physiologic doses suggests that rodents are more prone to teratogenic effects from corticoids than humans. In addition, because there is a natural increase in glucocorticoid production during pregnancy, most women will require a lower exogenous steroid dose and many will not need corticoid treatment during pregnancy.

Nonteratogenic Effects: Hypoadrenalism may occur in infants born of mothers receiving corticosteroids during pregnancy. Such infants should be carefully observed.

Nursing Mothers: It is not known whether triamcinolone acetonide is excreted in human milk. Because other corticosteroids are excreted in human milk, caution should be exercised when Nasacort Nasal Inhaler is administered to nursing women.

Pediatric Use: Safety and effectiveness have not been established in children below the age of 12. Oral corticoids have been shown to cause growth suppression in children and teenagers, particularly with higher doses over extended periods. If a child or teenager on any corticoid appears to have growth suppression, the possibility that they are particularly sensitive to this effect of steroids should be considered.

ADVERSE REACTIONS: In controlled and uncontrolled studies, 1257 patients received treatment with intranasal triamcinolone acetonide. Adverse reactions are based on the 567 patients who received a product similar to the marketed Nasacort canister. These patients were treated for an average of 48 days (range 1 to 117 days). The 145 patients enrolled in uncontrolled studies received treatment from 1 to 820 days (average 332 days).

The most prevalent adverse experience was headache, being reported by approximately 18% of the patients who received Nasacort. Nasal irritation was reported by 2.8% of the patients receiving Nasacort. Other nasopharyngeal side effects were reported by fewer than 5% of the patients who received Nasacort and included: dry mucous membranes, naso-sinus congestion, throat discomfort, sneezing, and epistaxis. The complaints do not usually interfere with treatment and in the controlled and uncontrolled studies approximately 1% of patients have discontinued because of these nasal adverse effects.

In the event of accidental overdose, an increased potential for these adverse experiences may be expected, but systemic adverse experiences are unlikely (see OVERDOSAGE section).

OVERDOSAGE: Acute overdosage with this dosage form is unlikely. The acute topical application of the entire 15 mg of the canister would most likely cause nasal irritation and headache. It would be unlikely to see acute systemic adverse effects if the nasal application of the 15 mg of triamcinolone acetonide was administered all at once.

Caution: Federal (U.S.A.) law prohibits dispensing without prescription. Please see product circular for full prescribing information.

REFERENCES:

1. Data on file, Rhône-Poulenc Rorer Pharmaceuticals Inc.
2. Ziemniak JA: Pharmacokinetics of intranasal triamcinolone acetonide. *J Respir Dis* 1991;12 (3, Suppl):S41-S42.
3. Feiss G, Morris R, Rom D, et al: A comparative study of the effects of intranasal triamcinolone acetonide aerosol (ITAA) and prednisone on adrenocortical function. *J Allergy Clin Immunol* 1992;89:1151-1156.
4. Findlay S, Huber F, Garcia J, et al: Efficacy of once-a-day intranasal administration of triamcinolone acetonide in patients with seasonal allergic rhinitis. *Ann Allergy* 1992;68(3):228-232.



Marketed by:

RHÔNE-POULENC RORER

RHÔNE-POULENC RORER PHARMACEUTICALS INC.

500 ARCOLA ROAD
COLLEGEVILLE, PA 19426

Innovators in Respiratory Care

NA06L794(7357)B 7/94 FC#94-F08 ©1994 Rhône-Poulenc Rorer Pharmaceuticals Inc. Printed in U.S.A.

QD STAYING POWER

Positron emission tomography (PET) image of ^{11}C -triamcinolone acetonide following intranasal administration of Nasacort[®]

ONCE DAILY[®]
Nasacort[®]

(triamcinolone acetonide) Nasal Inhaler



***Provides comfortable, prompt relief
of allergic rhinitis and effective QD dosing***

- Nasacort remains in the nasal mucosa with no measurable effect on HPA function^{1-3*}

Duration of acquisition of the PET image was approximately 55 minutes due to ^{11}C decay ($t_{1/2}$ of 20 minutes).¹ (n=2)

- Nasacort provides prompt relief for many patients — symptom reduction may occur as soon as 24 hours after starting therapy⁴
- Nasacort provides effective QD dosing — 2 puffs/nostril/day effectively controls symptoms in most patients; however, QD dosing can be increased to 4 puffs/nostril/day when necessary

Please see brief summary of prescribing information on adjacent page.

* In doses up to 440 mcg/day.³

Nasacort...Once Is Enough

"The perinatologists are very knowledgeable. Very personal. Very accessible."

James Maher, M.D. OB GYN


"My partner and I have consulted with them for a variety of clinical problems and we've always received an immediate response. They've been flexible in their level of involvement, from 'curbside consults' to total patient management. It's really whatever we're most comfortable with. They have always provided excellent state-of-the-art care. Care we know we can trust. It's been a very positive addition for us...a relationship we really like."

Through a partnership with UC Davis Medical Center, five perinatolo-

gists are available to work with Mercy physicians in coordinating care for high-risk patients. The perinatologists are available

24 hours a day, seven days a week to provide on-site and/or phone consultation. Antepartum clinic services are scheduled three half-days each week at Mercy General Hospital and Mercy San Juan Hospital, with scheduled visits available at any Mercy facility.

To learn more about Mercy's perinatal consultation services call Mercy General at 453-4140 or Mercy San Juan at 537-5339.



**Mercy
Healthcare
Sacramento**

**UCD
UC DAVIS
MEDICAL CENTER MC**

Classified Advertisements

The rate for each insertion is **\$8 per line** (six words per line) with **five lines (\$40) minimum**. Confidential box number charge: \$10 each month.

Classified display rates \$70 per inch. Maximum sizes: 1 column by 5 inches or 2 columns by 2 inches (2 1/8 inches per column). Larger classified ad space by special arrangements.

Copy for classified advertisements should be received not later than **first of the month preceding issue**. All copy must be typed or printed. • Classified advertisers using Box Numbers forbid the disclosure of their identity; your inquiries in writing will be forwarded to Box Number advertisers. Although The Western Journal of Medicine believes the classified advertisements in these columns to be from reputable sources, we do not investigate the offers made and assume no liability concerning them. The right is reserved to reject, withdraw, or modify all classified advertising copy in conformity with the decisions of the Advertising Committee.

Please Type or Print Advertising Copy

Classified Advertisements Are Payable in Advance

CLASSIFIED ADVERTISEMENTS
THE WESTERN JOURNAL OF MEDICINE
PO BOX 7602, SAN FRANCISCO, CA 94120-7602
(415) 882-3376
FAX: (415) 882-3379

PHYSICIANS WANTED

Western States OPENINGS

Many multispecialty groups and hospitals have asked us to recruit for over 300 positions of various specialties. Both permanent and locum tenens. Send CV to:

Western States Physician Services, 5627 E. Kings Canyon, Ste 156, Fresno, CA 93727, or call (800) 873-0786.

REWARDING OPPORTUNITY to practice the full range of Family Medicine (with Obstetrical option if desired) in a long-standing community health center. BC/BE Family Practitioners needed to join existing staff composed of Family Physicians, Internists, and Pediatricians on the Waianae Coast. Academic positions also available. Full benefits package and competitive salary. If interested, call or send CV to Pua Kalawa, Waianae Coast Comprehensive Health Center, 86-260 Farrington Highway, Waianae, HI 96792; (808) 696-7081.

PUGET SOUND. BC/BE Family Practitioners to affiliate with 115 physician multispecialty group, located 25 miles north of Seattle. Traditional Family Practice position available at new Silver Lake satellite. Opportunity for exceptional personal and professional lifestyle. Positions offer competitive salary with excellent benefits. Available September 1994. Send CV to J.G. Finley, MD, The Everett Clinic, 3901 Hoyt Ave, Everett, WA 98201.

RAPIDLY GROWING, NEWLY FORMED multispecialty group seeking a BC/BE Family Physician with California license. Guaranteed salary with many incentives, benefits, and all expenses paid. Beautiful valley, great schools, affordable housing and many recreational opportunities. Submit résumé to Hemacinto Medical Group, 2390 E Florida Ave, #101, Hemet, CA 92344, or call (909) 652-2252.

INTERNIST/FAMILY PRACTICE. Positions for well loved multidisciplinary Geriatric health center. Part of east San Francisco bay area community clinic network. Participation in hospital and call coverage desired. Resident teaching and UCSF affiliation possible. Call (510) 644-6060.

PHYSICIANS WANTED

NEVADA: MD BC/BE OCCUPATIONAL MEDICINE/FAMILY PRACTICE

Physician needed for busy, Urgent Care/Industrial Medicine, walk-in clinics. Flexible hours, generous benefits, excellent salary. Excellent locations in exciting Las Vegas/Laughlin area offer numerous recreational activities and the finest entertainment. CV to:

**S. Schlotter
PO Box 95637
Las Vegas, NV 89193
(702) 731-1278**

SIMPLY THE BEST LOCUM TENENS PLACEMENT OPPORTUNITIES nationwide for Internal Medicine, Pediatrics, and Family Practice. Try a practice before you sign. Call The Locums' Company today at (800) 735-6286.

SOUTHERN CALIFORNIA. Great private practice opportunity in an affluent Orange county community. Primary Care practice with tremendous growth potential. BC in Family Practice or Emergency Medicine. Contact Dr Joss, (714) 777-1773 or send CV to 21580 Yorba Linda Blvd, #102, Yorba Linda, CA 92687.

SOUTHERN IDAHO URGENT CARE. Expanding Immediate Care with emphasis on quality. Live and work near a variety of outdoor recreation. Located near Yellowstone Park, Sun Valley, Jackson Hole, and the Tetons. This established organization will be opening a new facility. Reply with CV in confidence to PO Box AK, Twin Falls, ID 83303.

DEAR DOCTOR:

If your goals include a quality lifestyle, a dynamic medical community, excellent schools/universities, and beautiful and affordable housing, then we have the ideal practice opportunity for you!

HOLY FAMILY HOSPITAL and the MEDICAL STAFF are working together to meet the healthcare demands of our 150,000 patient population. There is an IMMEDIATE need for BC/BE physicians in the following specialties:

- FAMILY PRACTICE
- INTERNAL MEDICINE
- GENERAL SURGERY
- OB/GYN

SPOKANE, WASHINGTON (370K metro population) is the regional Healthcare and Cultural center offering a sound economy, unlimited outdoor recreation and a mild four season climate.

CONTACT with CV to: **Nancy Chaffins**



**N. 5633 LIDGERWOOD
SPOKANE, WA 99207
(509) 482-2164
FAX: (509) 482-2456**

HCR

**Health Care Recruiting
NATIONWIDE
Search Firm**

**James Ransom
160 NW Irving
Ste 201-B
PO Box 1221
Bend, OR
97709
(800) 323-1732
(503) 382-1732**

NORTHERN CALIFORNIA RECREATION AREA. Multispecialty group has immediate opening for an Internal Medicine practitioner with a particular interest in Critical Care. Clinical activities involve full range of Internal Medicine outpatient and inpatient practice. Beautiful northern California location offers abundant recreational opportunities as well as small town living. Competitive salary and comprehensive benefit package. Please send CV to 10978 Donner Pass Rd, Truckee, CA 96161.

SAN DIEGO. COMMUNITY HEALTH CENTER, serving Latino, underserved population, seeks BC/BE Family Practitioner or Internist. Tremendous job satisfaction, competitive salary, comprehensive benefits, loan repayment possible. Contact Joseph Browne, MD, Medical Director, Logan Heights Family Health Center, 1809 National Ave, San Diego, CA 92113; (619) 234-8171.

ENDOCRINOLOGIST OR INTERNIST WANTED to gradually take over large practice in San Francisco bay area. FAX inquiry to (415) 697-1043.

(Continued on Page 100)

FAMILY PRACTICE • OB/GYN • PEDIATRICS

Come Enjoy a Quality Lifestyle!

SPOKANE, WASHINGTON - this unique city offers you affordable housing, excellent schools and universities, a regional arts and cultural center, and unlimited recreational opportunities in this mild four season climate.

Come Enjoy a Quality Practice!

ROCKWOOD CLINIC, P.S., a physician directed multi-specialty medical group practice offering both primary and tertiary services at six Spokane area locations seeks board certified primary care physicians for a new satellite clinic located in a rapidly growing suburban area.

Come practice with an established group providing you the environment to: Maintain your autonomy, concentrate on patient care, be relieved from business hassles, have strong collegial support and a favorable call schedule. Substantial benefits package includes: a competitive salary leading to early share holder status, six weeks vacation and paid CME.

CONTACT: Colleen Mooney

Rockwood Clinic P.S.
E. 400 5th Ave., P.O. Box 3649
Spokane, WA 99220-3649
Phone (509) 838-2531
Fax (509) 455-5315



(Continued from Page 99)

PHYSICIANS WANTED

THE SOUTHWEST IS CALLING

Leading medical providers in Arizona, Nevada, Utah, Colorado, and New Mexico have asked us to find the best available BC/BE physicians in the specialties of Orthopedic Surgery, Internal Medicine, Family Practice, Pediatrics, Urgent Care, OB/GYN, Psychiatry, Hematology/Oncology, Radiology, Occupational Medicine, ENT/MED/PED, Cardiology, Nephrology, and Pulmonology. Top benefits, profit sharing, guarantee first two years, plus incentive pay, early shareholder. Please call CPR Tucson, (800) 658-9166, FAX (602) 322-2676, or in Phoenix, (800) 657-0354, FAX (602) 433-9548.

NORTHERN CALIFORNIA—BC/BE GENERAL INTERNIST sought to join progressive prepaid multispecialty group practice at the Kaiser Permanente Medical Center in Santa Rosa. Department of Medicine includes 13 generalists and 10 specialists; call schedule is reasonable. Spanish fluency preferred. Free-standing medical clinic since 1980; 106-bed hospital on same campus since 1990. Located on the northern edge of the San Francisco bay area, Santa Rosa offers a rural/suburban lifestyle with easy access to the amenities of a major metropolitan area. Competitive salary, generous benefits and comprehensive benefit package. For more information, send CV and cover letter to Gordon Leung, The Permanente Medical Group, Inc, Physician Recruitment Services, Dept 64, 1814 Franklin, 4th Floor, Oakland, CA 94612. EOE.

PHYSICIANS WANTED

ELKO REGIONAL MEDICAL CENTER NEVADA'S OLDEST MULTISPECIALTY CLINIC

is currently seeking an OB/GYN, two Family Practice Physicians, a Pediatrician, and an Orthopedic Surgeon. Elko is a growing, beautiful rural area. It has a booming economy with a flourishing practice opportunity. Six month salary guarantee leading to a full partnership. Great benefit package.

Please contact Jane Descutner
762 14th St, Elko, NV 89801
(702) 738-3111

CALIFORNIA, ACADEMIC, MULTISPECIALTY group practice seeks Family Practitioners, Internists, and Pediatricians for Primary Care practice opportunities. These physicians will qualify for faculty appointment in the School of Medicine. They will admit patients to the school's three teaching hospitals. They will refer specialty cases to faculty colleagues. Competitive salaries are being offered with potential for incentive bonus. A comprehensive benefit package is provided. Respond to Loran Hauck, MD, Medical Director, Loma Linda Faculty Medical Group, 11370 Anderson St, Ste 3000, Loma Linda, CA 92354; (909) 799-3315.

SOUTHERN CALIFORNIA. BC FAMILY PRACTITIONER, some administrative responsibilities, light call, competitive guarantee, benefits. High desert community. Call Patience Schock, (800) 765-3055, or (314) 725-1892.

NO ADMINISTRATION NO CALL NO TAXES

What this excellent opportunity does have is low crime, affordable housing, top-rated public schools, Reno, Lake Tahoe, and much more. This is your opportunity to work as an Emergency Room physician and gain a level of independence that so few physicians can make claim to. You choose a three- or four-day work week, enjoy a flexible schedule and earn a comfortable six-figure income where your hard-earned dollar goes a long way.

For more information on this opportunity, please send your CV to:

MERRITT, HAWKINS, & ASSOCIATES
222 W Las Colinas Blvd, Ste 1920
Irving, TX 75039

Please reference 2704
or call John Paulk or Steve Welker
at (800) 288-1210 or (714) 757-7750.

INTERNAL MEDICINE. SALEM, OREGON. 20 plus multispecialty group in Oregon's beautiful Willamette Valley seeks BC/BE Internist. Generous call rotation. Salary plus incentive, outstanding benefits. 45 minutes from Portland. Savor city life without the headaches. Natural wonders and recreational amenities abound. Contact Yvonne Carscadden, (503) 399-2470, or send CV to Salem Clinic, 2020 Capitol NE, Salem, OR 97303.

SALT LAKE CITY—URGENT CARE/FAMILY PRACTICE. Six-year-old center in upper middle class community. BC preferred, early partnership available. Great recreation area. Work Net, PO Box 26692, Salt Lake City, UT 84199.

ORTHOPEDIC—HAWAII. \$200,000. Clear speech. CVs to LAM Associates, Dept W, 444 Hobron Ln, #207H, Honolulu, HI 96815-1229; Call Pat Lam, (800) 258-4526, 11-11 your time.

NORTHERN CALIFORNIA RECREATION AREA. Multispecialty group has immediate opening for a Family Practice physician. Clinical activities involve full range of Family Practice outpatient and inpatient practice. Beautiful northern California location offers abundant recreational opportunities as well as small town living. Competitive salary and comprehensive benefit package. Please send CV to 10978 Donner Pass Rd, Truckee, CA 96161.

NEXT CLASSIFIED DEADLINE:
AUGUST 1 FOR SEPT ISSUE

(Continued on Page 101)

(Continued from Page 100)

PHYSICIANS WANTED

ROCKY MOUNTAIN WEST AND SOUTHWEST NEED PHYSICIANS. All specialties needed. Urban, rural, solo, group opportunities, all close to mountain recreation. Call Rita Longino at (800) 279-5267 or FAX CV to (800) 467-1246 or send CV to WHS, PO Box 2107, Corrales, NM 87048-2107.

ASSOCIATE IN PEDIATRICS. Kern Medical Center, Bakersfield, California, a teaching hospital affiliated with UCLA and UCI Schools of Medicine, seeks an Associate in the Division of Pediatrics. Prerequisites include eligibility or certification by the American Board of Pediatrics, strong interest in teaching and qualifications for faculty appointment in UCLA Department of Pediatrics. Comprehensive salary and benefit package. A part-time private practice is permitted. Medical center is in central California, a mid-sized urban community with moderate cost of living. Send CV and inquiries to Navin Amin, MD, Chairman, Department of Family Practice/Pediatrics, Kern Medical Center, 1830 Flower St, Bakersfield, CA 93305.

SAN FRANCISCO BAY AREA. Physician wanted for growing Occupational Medicine practice, full-time, competitive salary, benefits. Call Dr. Boni at (510) 614-3715.

BC OR RECENTLY BE PHYSICIANS NEEDED. Los Angeles and Seattle metropolitan areas: Family Practice, Pediatrics, OB/GYN, Industrial Medicine, Urgent Care, and Internal Medicine. Northern Arizona: Invasive/Noninvasive Cardiologists and Internal Medicine. Call Chris Warner, Panther Enterprises Physician Recruiting and Placement, (800) 235-7601.

NEW MEXICO. Traditional Family Practice with no OB. Premier health care system provides a stable, secure environment and eliminates unnecessary administrative hassles. Attractive call schedule of one in six. Above average income as compared with groups across the nation. Superior benefits. Local state university. Ballet, symphony, and theater. Unsurpassed outdoor recreation with year-round golf, plus downhill skiing close by. Contact Diane Safner, (800) 765-3055, FAX (314) 726-3009.

EXCELLENT OPPORTUNITY FOR INTERNAL MEDICINE PHYSICIAN in private practice multispecialty physician group in San Francisco. Income guarantee. No investment. Forward CV to Box 263, The Western Journal of Medicine, PO Box 7602, San Francisco, CA 94120-7602.

CALIFORNIA-SAN LUIS OBISPO AREA. Position available in Urgent Care center on the beautiful central California coast. Competitive compensation, malpractice paid. Prefer physicians with experience or residency training in Emergency Medicine or Family Practice. Send CV to Medical Director, 283 Madonna Rd, Ste B, San Luis Obispo, CA 93405.

PACIFIC NORTHWEST AND ROCKY MOUNTAIN/SOUTHWEST LOCATIONS. Locum tenens assignments in Emergency Medicine, Primary Care, and Radiology. Urgent need for locum tenens. Benefits include malpractice, lodging, and transportation. Assignments vary in duration. Permanent placement also available. Call or write Lorie or Susan, Interim Physicians, 4155 E Jewell, #1018, Denver, CO 80222; (800) 669-0718.

BC/BE FAMILY PRACTITIONER with interest in OB and a commitment to caring for the underserved needed to join clinics in Grandview and Walla Walla, Washington, and Hermiston, Oregon. All clinics located in rural settings with abundant recreational activities. Competitive salary, Public Health Service loan repayment slots, and excellent benefit package including paid malpractice. Contact Mayling Chin, Recruiting Specialist, or Ann Garza, Director of Personnel at Yakima Valley Farm Workers Clinic, PO Box 190, Toppenish, WA 98948, or (509) 865-5898.

**A few
reasons
why you
should
advertise in
WJM:**

- ✓ reach 50,000 physicians nationwide
- ✓ concentrated audience in 10 western states
- ✓ affordable ad rates
- ✓ friendly staff

**Call
Classified
Advertising
for more
information:
(415) 882-3376**



"I was worried I might be giving up continuity of patient care with an HMO. Not so with CIGNA. I have my own patient base, enabling me to give consistent, personalized medical care."



"At CIGNA HealthCare, I have the freedom to enjoy an active social, as well as professional, life."

CIGNA HealthCare gives you the freedom to focus on what's most important...the practice of good medicine. We take care of the accounting, office management and more. And our locations offer you some of the best practice opportunities and lifestyles found anywhere. We currently have the following positions available:

SOUTHERN CALIFORNIA Los Angeles, Orange, Riverside & San Bernardino Counties

Dermatologist
Family Physicians
Internists

OB/GYNs
Pediatricians
Urgent Care/FP & Peds

ARIZONA Phoenix & Tucson

Family Physicians
Geriatricians
Internists
Invasive Cardiologist

OB/GYNs
Pediatricians
Urgent Care Physicians

As part of our team, you'll enjoy a predictable schedule. What's more, CIGNA HealthCare offers competitive salaries, comprehensive benefits, and the resources of a healthcare leader. For more information, call or send your CV to:

California: CIGNA Medical Group, Physician Recruitment, 505 N. Brand Blvd., Suite 400-49, Glendale, CA 91203, (800) 468-9013. EOE.

Arizona: CIGNA HealthCare of AZ, Physician Recruitment, 11001 N. Black Canyon Hwy., Suite 401-49, Phoenix, AZ 85029, (800) 252-2471. EOE.



CIGNA HealthCare

A Business of Caring.

(Continued on Page 102)

PHYSICIANS WANTED

PRIMARY CARE

OREGON &
S.W. WASHINGTON

Northwest Permanente, P.C., a professional group of physicians providing medical services to 380,000 members of Kaiser Permanente in Oregon and SW Washington, has full-time and part-time opportunities in general family practice or urgent care for BC/BE Family Physicians and Internists in the Portland/Vancouver and Salem, OR areas and Longview, WA. In Salem, opportunities exist for Family Physicians or Internists with a special interest or expertise in geriatrics.

Our program offers a professionally stimulating environment, a quality lifestyle in the Pacific Northwest, signing bonus and a competitive salary/benefits package. Forward inquiry and C.V. to: W. J. Weiland, M.D., Regional Medical Director, NORTHWEST PERMANENTE, P.C., 2701 N.W. Vaughn St., #300, Portland, OR 97210-5398. EOE.



PHYSICIANS IN INTERNAL MEDICINE and General Practice, and Psychiatrists, Chief, senior, and staff positions, full-time and part-time. The California Department of Corrections has positions available in one of our newer prison complexes in the Wasco State Prison Reception Center near Bakersfield and San Luis Obispo, with easy access to the coast and mountains, and affordable housing in open country for great family living. We offer competitive salary and excellent benefits, and our new safety retirement package. For more information on the positions at Wasco, call David Lewengood, MD, Chief Medical Officer, (805) 239-6696, or FAX your résumé to (916) 327-1804. EOE.

EXPAND YOUR HORIZONS! Whether you are looking for a change of pace, a fresh start, or just a change of scenery, we are your source for up-to-date information on practice opportunities from the lakes of Minnesota to the mountains of upstate New York. We currently represent hospitals and clinics throughout the midwest and northeast in a variety of Primary Care and surgical specialties, and subspecialties. Locations and settings vary from prominent, multi-site clinics, to traditional resort-town practices. For specific answers and pertinent information, please call (800) 243-4353 or send your CV to Strelcheck & Associates, Inc, 10624 N Port Washington Rd, Mequon, WI 53092.

PEDIATRICIAN to join a hospital-based Pediatric practice in northern New Mexico. Twenty miles north of Santa Fe, located in the Rio Grande Valley. Easy access to skiing and outdoor sports. Employment situation with competitive salary. Contact Bill Norris, Presbyterian Healthcare Services, (800) 545-4030, ext 6320, for further details.

LOOKING FOR THE PERFECT POSITION? Call (415) 882-3376 to place your ad under "POSITION WANTED."

PHYSICIANS WANTED

THE VA MEDICAL CENTER,
PRESCOTT, ARIZONA

is seeking a BC/BE Internist or Family Practice Physician. Regular hours. Experience with Holter monitors, treadmill testing, and/or endoscopy desirable but not necessary. Prescott is a lovely area with beautiful surroundings, clean air, pleasant lifestyle, wonderful dry four season climate. Interested physicians may call (602) 445-4860, ext 6640, or send CV to Chief, Medical Service, VA Medical Center, Prescott, AZ 86313.

EOE

FAMILY PRACTICE AND INTERNAL MEDICINE.

OREGON—Enthusiastic, nine-member Primary Care group seeks BC/BE Internist and Family Physician for growing resort community. Hospital owned group provides generous salary, benefits, fabulous new offices, etc. Terrific location just off the ocean, abundant recreation, one hour from university. Contact Jean Erickson, PROSEARCH, 317 SW Alder, Ste 1160, Portland, OR 97204-2530; (800) 622-3377, FAX (503) 222-1262.

SAN FRANCISCO BAY AREA. Energetic, recently trained BC/BE Pediatrician needed for 18 physician satellite of Palo Alto Medical Clinic, a 160 physician multispecialty group with a national reputation for innovation and excellence. Broad practice in growing bay area community. Excellent location with convenient access to San Francisco and Stanford. Competitive compensation/benefits package. Early partnership. Please send CV to David Hooper, PAMC, Fremont Center, 39500 Liberty St, Fremont, CA 94538.

CALIFORNIA MULTISPECIALTY. Urgent Care Director, Dermatologist, Radiologist, Otorhinolaryngologist, General Surgeon, Cardiologist, Internal Medicine, Pediatrician, Gastroenterologist, Orthopedist, General/Family Practitioner, Obstetrician/ Gynecologist. Excellent opportunity for physicians to join 400 member multispecialty medical group serving the greater Los Angeles, San Fernando Valley, and Orange county areas. Over 40 locations. Large fee-for-service and prepaid practice, no Medi-Cal. Excellent compensation program based on guarantee plus incentive, profit sharing and pension plan. Group provides health, dental, life, and malpractice. Partnership in real estate and medical corporation available. Send CV to Ron McDaniel, Assistant Administrator, Mullikin Medical Center-5, 17821 S Pioneer Blvd, Artesia, CA 90701.

CALIFORNIA. MONTEREY BAY. Full-/part-time positions available with Monterey Bay's largest and most successful Urgent Care network. Generous guarantee, incentive plan, and benefit package. Malpractice covered. Practice in California's most beautiful coastal recreational area. BC/BE Emergency Medicine or Family Practice specialists preferred. Contact Rob Colyn, VP of Personnel, Doctors on Duty Medical Clinics, 19000 Portola Dr, Ste 100, Salinas, CA 93908; (408) 455-2424.

ENJOY THE GREAT SOUTHWEST. Thomas-Davis Medical Centers, one of Arizona's fastest growing multispecialty groups is seeking BC/BE Internal Medicine, Family Practice, OB/GYN, and Hematology/Oncology Physicians. 200 physicians strong, TDMC has provided health care services in Arizona for more than 75 years. For more information regarding this practice opportunity, contact William Trainor, TDMC, 6135 N 7th St, Phoenix, AZ 85014, or call (800) 539-2529, or FAX CV to (602) 530-6255.

PHYSICIANS WANTED

NORTHWEST REGION

Physicians needed to join a multispecialty group, partnership, or solo practice, due to the explosive population growth. BC/BE physician specialties:

- FAMILY PRACTICE
- CARDIOLOGY
- INTERNAL MEDICINE
- PEDIATRICS
- PSYCHIATRY
- ORTHOPEDICS

Excellent practice opportunities offer guaranteed income and a strong referral base.

Contact with CV to:

Marge Becker, Owner/Manager
BECKER PHYSICIAN PLACEMENT
4407 N Division, Ste 500
Spokane, WA 99207
(800) 945-4066/FAX (509) 484-6317

FAMILY PRACTICE PHYSICIAN needed for growing San Diego multispecialty group. Prefer English/Spanish speaking physician familiar with managed care.

Please mail or FAX CV to:

Howard Hsu, Administrator
Paradise Medical Associates
610 S Euclid Ave, Ste 201
National City, CA 91950

FAX (619) 479-6750

MARKS MEDICAL PLACEMENTS

Joyce Marks-President

Immediate opportunities for BC/BE physicians in South Carolina, Kentucky, Kansas, Georgia, Texas, Nevada, Louisiana, Washington, Southern, and Northern California; the BEST locations. Family Practice, Internal Medicine, OB/GYN, Pediatrics, Dermatology, Physician Assistants, Nurse Practitioners.

Please send CV to:

Joyce Marks-President
Marks Medical Placements
2170 Century Park East, #806
Los Angeles, CA 90067

Or Call: (310) 556-2126, FAX (310) 556-1604

AT NO COST TO PHYSICIAN



ACROSS THE WEST

Locum Tenens
All Specialties

Flexible schedules, competitive compensation, per diem, permanent potential. Call (800) 683-3500 or FAX (801) 392-1095.

(Continued from Page 102)

CPMG

AN IMMEDIATE POSITION is available for a full-time Internist for California Pacific Medical Group (CPMG), a San Francisco-based medical group with over 650 participating physicians and about 95,000 covered enrollees.

The position requires completion of an approved Residency Program in Internal Medicine.

Responsibilities include management of inpatients admitted to the California Pacific Medical Center and inpatient utilization management activities. This position offers an exciting opportunity for physicians who enjoy inpatient medicine.

This is a salaried position with competitive compensation and an excellent benefits package. Qualified applicants should submit their résumé and letter to:

California Pacific Medical Services
Organization
Human Resources
PO Box 640469
San Francisco, CA 94164-0469
(415) 749-4816

EOE

**GET
NOTICED!**

Call
WJM
**Classified
Advertising
for more
information.**

(415)
(882-3376)

P H Y S I C I A N

Natividad Medical Center is seeking Family Practitioners to join our Family Practice Residency Program and Affiliated Community Clinics.

- Residency affiliated with the University of California, San Francisco
- Modern, affordable health care campus on present site to be completed by 1997
- Community of 110,000, 17 miles inland from the Monterey Bay Area; moderate year round weather
- Applicants must be Board Certified/Board Eligible as a Family Practitioner
- Obstetrics preferred for Residency Faculty position; optional for community clinics

If this sounds like what you are looking for, and you are ready to join an energetic team, please ask for more information by contacting:

Richard Brunader, M.D.
Director, Family Practice Residency Programs
P.O. Box 81611, Salinas, CA 93912
408-755-4201.
AA/EOE.

 **NATIVIDAD
MEDICAL
CENTER...**

FRIENDLY PEOPLE-FAMILY MEDICINE

PRACTICE OPPORTUNITY
SUNNYVALE, (NORTHERN) CALIFORNIA
OCCUPATIONAL MEDICINE

EXCELLENT OPPORTUNITY. Large multispecialty group with an expanding Division of Occupational Medicine has an immediate opening for a qualified, energetic physician. We are seeking a career-minded physician with superb clinical and communication skills. Experience with managed care, computers, and teaching is desirable.

We are offering a full-time position with an opportunity to become a shareholder after 18 months.

For more information regarding this opportunity, please contact:

Kathleen Strawbridge
Medical Staff Coordinator
Sunnyvale Medical Clinic
301 Old San Francisco Rd
Sunnyvale, CA 94086
(408) 730-4309

 **Sunnyvale
Medical Clinic**

PHYSICIANS WANTED

NORTHWEST NEW MEXICO
FOUR CORNERS

Come to the canyons and high mesas of northwest New Mexico. Enjoy skiing, fishing, hunting, hiking, mountain biking, tennis, and golf. Friendly family-oriented community seeking full-time, long-term BC/BE physicians for our Level II **Emergency Room**, beginning this summer. In lieu of BC/BE, will consider a minimum of four years experience in a designated trauma center serving 12,000-plus patients per year. Competitive salary and benefits, medical school loan repayment with long-term contracts. Designated HPSA site. Also seeking Family Practitioner and Internists to provide inpatient, outpatient, and ICU care with hospital-owned clinic. Send CV to Jan Haase, c/o RMCH, 1901 Red Rock Dr, Gallup, NM 87301, or phone (800) 571-7823.

Also seeking BC/BE Family Practitioners and Internists for clinic affiliated with hospital; requires outpatient, inpatient and ICU skills. For information write or call number listed above.

PHYSICIANS WANTED**CALIFORNIA**

Primary Care Physicians and Radiologists needed to work as locum tenens statewide. High salary, paid malpractice. Work whenever and wherever you wish. Permanent placements as well. **INTERIM Physicians/ Western Physicians Registry:** Northern California, Jim Ellis, Director, (800) 437-7676. Southern California, Tracy Zweig, Director, (800) 635-3175.


**Classified
Advertising is
Affordable
and Effective**

For details see the Classified Advertising form at the end of the journal. Or call

Classified Advertising:
(415) 882-3376.

(Continued on Page 104)

PHYSICIANS



We are announcing opportunities for you to serve your country as an Air Force Reserve physician/officer. You can make new professional associations, obtain CME credit and help support the Air Force mission. For those who qualify, retirement credit can be obtained as well as low cost life insurance. One weekend a month plus two weeks a year or less can bring you pride and satisfaction in serving your country.

Call: (800) 253-6189

Or Fill Out Coupon and Mail Today!

To: Air Force Reserve
151 N Sunrise
Ste 1106
Roseville, CA 95661

Name

Address

City State Zip

Phone Prior Service? Yes ☐ No ☐

Medical Specialty Date of Birth

AIR FORCE RESERVE

25-404-0011

A GREAT WAY TO SERVE

(Continued from Page 103)

CALIFORNIA. Ambulatory Care/Family Practice-CEP is a partnership of Ambulatory Care and Emergency Medicine specialists. We currently staff nine free-standing clinics in northern, central, and southern California, and have upcoming openings for physicians specializing in Family Practice. We offer shared ownership, excellent compensation, health, and disability insurance, retirement program, and many other benefits. For more information, send CV or call John Gravette, CEP, 2101 Webster St, Ste 1050, Oakland, CA 94612; (800) 842-2619.

PORTLAND, OREGON. BC/BE in group practice. Rapid population growth and an exceptional economic picture make this an ideal environment for successful practices. Excellent compensation, benefits, and call. Affiliated with the Sisters of Providence Catholic Health System. Affirmative action employer. Immediate opportunities and openings for 1995 graduates. Send CV and references to Mark May, Sisters of Providence Health System, 4805 NE Glisan St, Portland, OR 97213; (503) 230-6155, FAX (503) 230-6858.

ORTHOPEDIST-BC/BE, California licensed, needed for San Francisco based multispecialty medical practice. Primarily forensic medical practice (evaluation and expert witness evaluations in workers' compensation, personal injury, etc). Excellent opportunity for experienced clinician looking to emphasize evaluation and consultation practice as opposed to heavy treatment based practice. Full-time and part-time employment available, exceptionally high income potential, full benefits, and 401K. Submit CV and letter stating professional goals and availability to Administrator, 2040 Polk St, Box 337, San Francisco, CA 94109.

COLORADO FAMILY PRACTICE PHYSICIAN

BC Family Physician to join a multisite community health center serving low income families in Northwest metropolitan Denver. Position includes faculty appointment at the University of Colorado Department of Family Medicine and resident training opportunities. Competitive salary and comprehensive fringe benefit package. Work in a teaching environment with an interdisciplinary team dedicated to promoting health in an underserved population. Please send CV to **CLINICA CAMPESENA FAMILY HEALTH SERVICES**, 1345 Plaza Ct N, Unit 1A, Lafayette, CO 80026. Or call Pete Leibig, Executive Director, at (303) 665-9310 for more information.

The Western Journal of Medicine
Classified Advertising
PO Box 7602
San Francisco, CA 94120

PHYSICIAN IN GENERAL PRACTICE wishes to retire. Looking for doctor to take over practice, office staff, and rent his building. Call (209) 674-4717. In growing town of central San Joaquin Valley.

OUTSTANDING OPPORTUNITY IN WINE COUNTRY. Internist or Infectious Disease Physician can find a fully furnished and equipped 20-year practice ready to be assumed Summer or Fall 1994. Located in the heart of the California Wine Country. Beautiful, 1,000 square-foot office in serene wooded setting. Only two blocks from superb 225-bed hospital. Price close to that of office alone. Hospital may assist buyer with financing. Reply to Box 296, The Western Journal of Medicine, PO Box 7602, San Francisco, CA 94120-7602.

PAIN TREATMENT CENTER. Medical General Practice. Established 1977. Priced for immediate sale. Central San Diego location. Fantastic highway signage. More than 15,000 patient charts. Part-time gross greater than 500K. Prior full-time gross greater than 1 million. Excellent potential for expansion. Sell 250K or best offer. Fully equipped. Suitable for Orthopedics, Neurology, Psychiatry, and Physical Therapy. K. Shandell, MD; (619) 291-1655.

SEATTLE. Thriving, well-established Family Practice three minutes from hospital and Puget Sound. 1993 receipts \$543,000. Strong patient base. Valuation report available. MDDS, Inc, (800) 280-6337, FAX (206) 842-9818.

ADVERTISERS:

Our FAX number is:

(415) 882-3379

OPHTHALMOLOGIST with 30 years experience desires to leave private practice. Would like to be employed by a company in the San Diego area for mutual benefit. Full- or part-time. Reply to Number 295, The Western Journal of Medicine, PO Box 7602, San Francisco, CA 94120-7602.

INDUSTRIAL MEDICINE/URGENT CARE. Experienced MD seeks position in San Francisco bay area. No malpractice history. Probity. (510) 735-1119.

CALIFORNIA: NURSE PRACTITIONERS AND PHYSICIAN ASSISTANTS PROVIDED for your clinical setting. Locum tenens and permanent placements through Western Practitioner Resources, California's most active, most respected placement service for Nurse Practitioners and Physician Assistants. For further information contact Heidi Bourne, RN, Director, (800) 345-5859.

SIMPLY THE BEST Locum Tenens Coverage

Family Practice • Internal Medicine • Pediatrics



The Locums' Company
1-800-735-6286

OB/GYN. BC, FACOG. American graduate with many years experience seeks locum tenens position in California. Smaller city preferred. Some interest in permanent, part-time position. Some Spanish spoken. Call (805) 937-8963, or FAX the same number.

(Continued on Page 105)

(Continued from Page 104)

PRACTICES AVAILABLE

FAMILY PRACTICE, NORTHERN COASTAL CALIFORNIA. New, spacious office on the edge of Redwood National Park. Safe, clean, growing community. Busy growing practice. Good staff. Low percentage of Medicare and Medicaid. 1993 gross \$176,000, 30 hours per week. Contact Gary Schaub, PO Box 69155, Portland, OR 97201; (503) 223-4357.

GENERAL ENT-ALLERGY PRACTICE FOR SALE. Excellent opportunity to live and practice in desirable Northern California location near Stanford University. Close to Carmel, San Francisco, and wine country. Available July 1, 1994. Assume lease, price negotiable, terms available. Call (415) 941-0901.

CONFERENCES

EIGHTH ANNUAL INTERNATIONAL WORKSHOP on Future Directions in Interventional Cardiology. September 23-25, 1994. Santa Barbara, CA. Fees: \$395 for ACC members; \$460 for non-members; \$250 for fellows-in-training, residents, physician assistants, nurses, and technologists. 22.5 Category 1 credit hours. For information, call American College of Cardiology, Extramural Programs, (800) 257-4739; FAX (301) 897-9745.

THERAPEUTIC POTENTIAL OF BIOLOGICAL ANTIOXIDANTS. International symposium, Tiburon, San Francisco Bay, September 29-October 1, 1994. For physicians, researchers. Mechanistic and physiological functions of oxygen radicals and antioxidants; effects on cardiovascular disease, HIV/AIDS, cancer. Contact Aleksandra Niedzwiecki, PhD, Linus Pauling Institute of Science and Medicine, 440 Page Mill Rd, Palo Alto, CA 94306; (415) 327-4064; FAX (415) 327-8564.

SERVICES

**BIMONTHLY
MEDICAL NEWSLETTER
On
HOW TO PASS BOARD
OF
INTERNAL MEDICINE**

For a **FREE** first copy mail your address label (self-sticking) with four (29 cents) stamps to

Medical Newsletter
389 E Mt Pleasant Ave
Livingston, New Jersey 07039.

Also available—similar newsletter on "How to Pass Board of Geriatric."

MEDICAL LITERATURE RESEARCH. Physician/educator/editor will do customized literature searching and analysis for medical or legal problems. Call Bill Milburn, MD, (303) 823-5083.

WJM
ADS
GET
RESULTS!

**MORE PHYSICIANS,
FASTER RESPONSE,
BETTER SERVICE.**

IT ALL ADDS UP.

CompHealth and Kron Medical, the nation's most experienced locum tenens groups, have joined forces. To bring you the largest pool of locum tenens physicians and allied health care professionals. Faster response. Competitive pricing. Flexible staffing options. Plus the tightest credentialing and most experienced support staff in the industry. Call CompHealth/Kron Today!

CompHealth/Krōn

THE NATION'S LOCUM TENENS SERVICE

1-800-453-3030

Atlanta ■ Chapel Hill ■ Grand Rapids ■ Salt Lake City

NEW LAWS PUT DOCTORS AT RISK

Do you understand the many new federal laws and regulations which apply to medical offices? We will perform an on-site survey of your office and practice, find the potential problems, and help you correct them. Our fees are lots easier to take than a million dollar lawsuit or large fine.

COMPLIANCE SURVEY SERVICE
(800) 605-9535

MEDICAL EQUIPMENT

OLYMPUS COLONOSCOPE (Model CF-P20L), 165 cm, excellent condition, includes all accessories and teaching attachment. Asking \$7,500. Halogen light source also available, \$475. Randall Nelson, MD, San Jose, (408) 297-5040.

**YOUR
ADVERTISEMENT
HERE**

BOOKS

**We have two new
FREE CATALOGS.**

1. Medical Books Catalog
2. Allied Health and Nursing Books Catalog

Call, write or come in
for your free copy today.


(206) 543-6582 • Fax 685-3921

**University
Book Store**

301 South Campus Center
University of Washington
Seattle, WA 98195
Open Mon.-Fri. 8 AM-5 PM;
Thurs. nights 'til 8;
Sat. 10 AM-4 PM

PHYSICIAN RESIDENT ALERT: IF YOU COULD USE OVER \$25,000 A YEAR— ANSWER THIS AD.

The U.S. Army's Financial Assistance Program (FAP) is offering a subsidy of over \$25,000 a year for training in certain medical specialties.



Here's how it breaks down - an annual grant, plus a monthly stipend and reimbursement of approved educational expenses.

You will be part of a unique health care team where you will find many opportunities to continue your medical education, work at state-of-the-art facilities, and receive outstanding benefits.


So, if you are a physician resident who could use over \$25,000 a year, contact an Army Medical Counselor immediately.

1-800-522-4914

ARMY MEDICINE. BE ALL YOU CAN BE.®

CMA Attorneys Announce the

1994 LEGAL UPDATE



The 1994 *California Physician's Legal Handbook* includes nearly 1400 pages designed to give you easy access and understandable explanations to the laws governing your practice.

The update includes the complete text as well as three new chapters: **Allied Health Professionals**, **Managed Care**, and **Workers' Compensation**. Written by CMA's attorneys for physicians and their advisors, this book takes the mystery out of the countless laws, regulations and court decisions applicable to California physicians.

Here's some of what you will learn about:

Abandonment / Discrimination
Advertising
Allied Health Professionals
AIDS & HIV
Billing Collections
Business Issues
Consent
Death / Organ Donation
Drug Prescribing & Dispensing

Drug Testing
Emergency Transfer
Expert Witness
Forgoing Treatment
Fraud and Abuse
Managed Care
Medical Board Reports
Medical Records
Medical Staffs

Medicare and Medi-Cal
Office Safety
Peer Review
Professional Liability
Reporting / Warning
Solicitation of Patients
Unprofessional Conduct
Workers' Compensation
...and much more!

The all new 1994 *California Physician's Legal Handbook* contains up-to-date LAWS, REGULATIONS, COURT DECISIONS and FORMS specific to California.

FOR MORE INFORMATION CALL 415/882-5175

For Impetigo

Put the *ban* on



For Impetigo

Dactroban[®]
mupirocin

***Power of an oral antibiotic
Safety of a topical***

- *Proven as effective as oral antibiotics^{1, 3, 4}*
- *Virtually eliminates the risk of systemic side effects²*
- *May result in fewer lost work and school days when compared to oral erythromycin⁴*